Arcadia Biosciences (RKDA) 10-K 25 Mar 20 2019 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2019	Mar. 18, 2020	Jun. 28, 2019
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	FY
Entity Registrant Name	Arcadia Biosciences, Inc.
Entity Central Index Key	0001469443
Entity Current Reporting Status	Yes
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding		8,654,095
Entity Public Float			$ 15,800,000
Entity Shell Company	false
Entity Emerging Growth Company	true
Entity Small Business	true
Extended Transition Period	true
Entity File Number	001-37383
Entity Tax Identification Number	81-0571538
Entity Address, Address Line One	202 Cousteau Place
Entity Address, Address Line Two	Suite 105
Entity Address, City or Town	Davis
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	95618
City Area Code	530
Local Phone Number	756-7077
Entity Incorporation, State or Country Code	DE
Trading Symbol	RKDA
Title of 12(b) Security	Common
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Document Annual Report	true
Document Transition Report	false
Documents Incorporated by Reference	Information required by Part III of this Annual Report on Form 10-K is incorporated by reference to the Registrant's Definitive Proxy Statement for its 2020 Annual Meeting of Stockholders, which proxy statement will be filed with the Securities and Exchange Commission within 120 days after the end of the fiscal year covered by this Form 10-K.

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 8,417	$ 11,998
Short-term investments	16,915	9,825
Accounts receivable	602	165
Unbilled revenue		3
Inventories, net — current	1,794	181
Prepaid expenses and other current assets	712	704
Total current assets	28,440	22,876
Property and equipment, net	1,799	395
Right of use asset	1,963
Inventories, net — noncurrent	364	746
Other noncurrent assets	8	7
Total assets	32,574	24,024
Current liabilities:
Accounts payable and accrued expenses	4,685	2,645
Amounts due to related parties	40	29
Notes payable - current	24
Unearned revenue — current	42	96
Operating lease liability - current	611
Other current liabilities	306	284
Total current liabilities	5,708	3,054
Notes payable - noncurrent	107
Operating lease liability - noncurrent	1,497
Common stock warrant liabilities	14,936	5,083
Other noncurrent liabilities	2,000	3,072
Total liabilities	24,248	11,209
Commitments and contingencies (Note 13)
Stockholders’ equity:
Common stock, $0.001 par value—150,000,000 shares authorized as of December 31, 2019 and December 31, 2018; 8,646,149 and 4,774,919 shares issued and outstanding as of December 31, 2019 and December 31, 2018, respectively.	49	45
Additional paid-in capital	214,826	191,136
Accumulated other comprehensive income	1
Accumulated deficit	(207,171)	(178,366)
Total Arcadia Biosciences stockholders’ equity	7,705	12,815
Non-controlling interest	621
Total stockholders' equity	8,326	12,815
Total liabilities and stockholders’ equity	$ 32,574	$ 24,024

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Common stock, par value	$ 0.001	$ 0.001
Common stock, authorized	150,000,000	150,000,000
Common stock, issued	8,646,149	4,774,919
Common stock, outstanding	8,646,149	4,774,919

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues:
Total revenues	$ 1,169,000	$ 1,464,000
Operating expenses (income):
Research and development	7,098,000	6,069,000
Change in fair value of contingent consideration	(1,000,000)
Selling, general and administrative	13,567,000	11,604,000
Total operating expenses	20,550,000	18,334,000
Loss from operations	(19,381,000)	(16,870,000)
Interest expense	(5,000)
Other income, net	466,000	394,000
Initial loss on common stock warrant and common stock adjustment feature liabilities		(4,000,000)
Change in fair value of common stock warrant and common stock adjustment feature liabilities	(9,243,000)	9,561,000
Offering costs	(708,000)	(2,555,000)
Net loss before income taxes	(28,871,000)	(13,470,000)
Income tax provision	(2,000)	(10,000)
Net loss	(28,873,000)	(13,480,000)
Net loss attributable to non-controlling interest	(68,000)
Net loss attributable to common stockholders	$ (28,805,000)	$ (13,480,000)
Net loss per share attributable to common stockholders:
Basic and diluted	$ (4.53)	$ (3.58)
Weighted-average number of shares used in per share calculations:
Basic and diluted	6,363,112	3,766,419
Other comprehensive income, net of tax
Unrealized gains on available-for-sale securities	$ 1,000
Other comprehensive income	1,000
Comprehensive loss attributable to common stockholders	(28,804,000)	$ (13,480,000)
Product
Revenues:
Total revenues	814,000	657,000
Operating expenses (income):
Cost of product revenues	885,000	661,000
License
Revenues:
Total revenues	67,000	150,000
Contract Research And Government Grants
Revenues:
Total revenues	$ 288,000	$ 657,000

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	June 2018 Offering [Member]	June 2019 Offering [Member]	September 2019 Offering [Member]	June 2018 Purchase Agreement [Member]	June 2019 Purchase Agreement [Member]	September 2019 Purchase Agreement [Member]	Common Stock [Member]	Common Stock [Member]June 2019 Offering [Member]	Common Stock [Member]March 2018 Securities Purchase Agreement [Member]	Common Stock [Member]June 2018 Purchase Agreement [Member]	Common Stock [Member]June 2019 Purchase Agreement [Member]	Common Stock [Member]September 2019 Purchase Agreement [Member]	Additional Paid-In Capital [Member]	Additional Paid-In Capital [Member]June 2018 Offering [Member]	Additional Paid-In Capital [Member]June 2019 Offering [Member]	Additional Paid-In Capital [Member]September 2019 Offering [Member]	Additional Paid-In Capital [Member]March 2018 Securities Purchase Agreement [Member]	Additional Paid-In Capital [Member]June 2018 Purchase Agreement [Member]	Additional Paid-In Capital [Member]June 2019 Purchase Agreement [Member]	Additional Paid-In Capital [Member]September 2019 Purchase Agreement [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive (Loss) Income [Member]	Non-controlling Interest [Member]
Stockholders Equity, Beginning Balance at Dec. 31, 2017	$ 8,007							$ 42						$ 175,223								$ (167,257)	$ (1)
Stockholders Equity, Beginning Balance, Shares at Dec. 31, 2017								2,134,153
Impact of adoption of Topic 606 | Topic 606 [Member]	2,371																					2,371
Issuance of shares related to employee stock option exercises	$ 963													963
Issuance of shares related to employee stock option exercises, Shares	44,354							44,354
Issuance of shares related to employee stock purchase plan	$ 6													6
Issuance of shares related to employee stock purchase plan, Shares								1,122
Issuance of shares					$ 4,978					$ 1	$ 2							$ (1)	$ 4,976
Issuance of shares, Shares										1,201,634	1,392,345
Issuance of placement agent warrants	526	$ 427												526	$ 427
Common stock adjustment feature	8,378													8,378
Offering costs					$ (912)														$ (912)
Stock-based compensation	1,550													1,550
Issuance of shares related to reverse stock split, Shares								1,311
Other comprehensive income	1																						1
Net loss	(13,480)																					(13,480)
Stockholders Equity, Ending Balance at Dec. 31, 2018	12,815							$ 45						191,136								(178,366)
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2018								4,774,919
Issuance of shares related to employee stock option exercises	$ 3													3
Issuance of shares related to employee stock option exercises, Shares	546							546
Issuance of shares related to employee stock purchase plan	$ 18													18
Issuance of shares related to employee stock purchase plan, Shares								8,536
Issuance of shares						$ 3,303	$ 6,571					$ 2	$ 1							$ 3,301	$ 6,570
Issuance of shares, Shares												1,489,575	1,318,828
Issuance of placement agent warrants			$ 198	$ 326												$ 198	$ 326
Issuance of shares related to the exercise of warrants			$ 5,269						$ 1							$ 5,268
Issuance of shares related to the exercise of warrants									1,053,745
Reclassification of common stock warrant liability balance with exercise	7,016													7,016
Offering costs						$ (489)	$ (808)													$ (489)	$ (808)
Stock-based compensation	2,287													2,287
Non-controlling interest contributions	689																							$ 689
Unrealized gains on available-for-sale securities	1																						1
Net loss	(28,873)																					(28,805)		(68)
Stockholders Equity, Ending Balance at Dec. 31, 2019	$ 8,326							$ 49						$ 214,826								$ (207,171)	$ 1	$ 621
Stockholders Equity, Ending Balance, Shares at Dec. 31, 2019								8,646,149

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (28,873,000)	$ (13,480,000)
Adjustments to reconcile net loss to cash used in operating activities:
Initial loss on common stock warrant and common stock adjustment feature liabilities		4,000,000
Change in fair value of common stock warrant and common stock adjustment feature liabilities	9,243,000	(9,561,000)
Change in fair value of contingent consideration	(1,000,000)
Offering costs	708,000	2,555,000
Depreciation	194,000	154,000
Lease amortization	708,000
Loss (gain) on disposal of equipment	3,000	(3,000)
Net amortization of investment premium	(180,000)	(193,000)
Stock-based compensation	2,287,000	1,550,000
Write down of inventory	304,000	310,000
Changes in operating assets and liabilities:
Accounts receivable	(437,000)	1,066,000
Unbilled revenue	3,000	2,000
Inventories	(1,535,000)	160,000
Prepaid expenses and other current assets	(8,000)	(151,000)
Other noncurrent assets	(1,000)
Accounts payable and accrued expenses	2,102,000	176,000
Amounts due to related parties	11,000	(1,000)
Unearned revenue	(54,000)	(312,000)
Other current liabilities	42,000	25,000
Other noncurrent liabilities		72,000
Operating lease payments	(715,000)
Net cash used in operating activities	(17,198,000)	(13,631,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of property and equipment	16,000	10,000
Purchases of property and equipment	(1,477,000)	(250,000)
Purchases of investments	(28,358,000)	(29,885,000)
Proceeds from sales and maturities of investments	21,450,000	24,150,000
Net cash used in investing activities	(8,369,000)	(5,975,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on notes payable	(8,000)
Proceeds from exercise of warrants	5,269,000
Proceeds from exercise of stock options and purchases through ESPP	21,000	969,000
Capital contributions received from non-controlling interest	689,000
Net cash provided by financing activities	21,986,000	22,479,000
Net (decrease) increase in cash and cash equivalents	(3,581,000)	2,873,000
Cash and cash equivalents — beginning of period	11,998,000	9,125,000
Cash and cash equivalents — end of period	8,417,000	11,998,000
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest	4,000
Cash paid for taxes	2,000	34,000
NONCASH TRANSACTIONS:
Offering costs in accounts payable and accrued expenses at end of period	20,000	23,000
Reclassification of common stock warrant liability balance with warrant exercises	7,016,000
Reclassification of unearned revenue to other short term liabilities		259,000
Reclassification of common stock adjustment feature liability balance to equity		8,378,000
Right of use assets obtained in exchange for new operating lease liabilities	2,328,000
Right of use assets obtained through modification of existing lease agreement	194,000
Fixed assets acquired with notes payable	139,000
Purchases of fixed assets included in accounts payable and accrued expenses	1,000
March 2018 Purchase Agreement [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from purchase agreement		10,000,000
Payments of offering costs relating to purchase agreement		(1,308,000)
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs related to purchase agreement		526,000
June 2019 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Offering	7,500,000
Payments of offering costs	(663,000)
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs	86,000
September 2019 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Offering	10,000,000
Payments of offering costs	(798,000)
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs	95,000
June 2018 Offering [Member]
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants from Offering		14,000,000
Payments of offering costs	$ (24,000)	(1,182,000)
NONCASH TRANSACTIONS:
Common stock warrants issued to placement agent and included in offering costs		$ 239,000

Description of Business

Description of Business	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Description of Business	Note 1. Description of Business Organization Arcadia Biosciences, Inc. (the "Company"), was incorporated in the state of Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, and Molokai, Hawaii. The Company was reincorporated in Delaware in March 2015. We are a leader in science-based approaches to developing high value crop productivity traits primarily in hemp, wheat, and soybean, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. We use state of the art gene-editing technology and advanced breeding techniques to develop these proprietary innovations which we are beginning to monetize through a number of methods including seed and grain sales, product extract sales, trait licensing and royalty agreements. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 7), which is jointly owned by us with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca , On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 6) to grow, extract, and sell hemp products. The new partnership, Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales. Reverse Stock Split In January 2018, the Company’s board of directors approved a reverse split of 1:20 on the Company’s issued and outstanding common stock which became effective on January 23, 2018. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. The reverse stock split did not change the total number of authorized shares of common stock which remained at one hundred and fifty million shares Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2019, the Company had an accumulated deficit of $207.2 million, cash and cash equivalents of $8.4 million, and short-term investments of $16.9 million. For the years ended December 31, 2019 and 2018, the Company had net losses of $28.9 million and $13.5 million, respectively, and net cash used in operations of $17.2 million and $13.6 million, respectively. The Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through March 2021, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional At this time, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak and impact of related responses. The continued spread of the outbreak could materially harm our business, results of operations, and financial condition. Due to this uncertainty and plans outside of management’s control, we may not be able to achieve and implement such plans within one year after the date that the financial statements are issued to address the substantial doubt that exists.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company, Verdeca LLC and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. The Company evaluates its relationships with its VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca LLC has no operations, assets or liabilities as of and for the years ended December 31, 2019 and 2018. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $68,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the year ended December 31, 2019. The non-controlling partner’s equity interests are presented as non-controlling interests on the Consolidated Balance Sheets as of December 31, 2019. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, stock-based compensation, fair value of certain equity instruments, and net realizable value of inventory. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates. Cash and Cash Equivalents The Company considers any liquid investments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2019 and 2018, a substantial portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits. Investments in Debt Securities Investments in debt securities are carried at fair value and classified as available-for-sale. Realized gains and losses on available-for-sale securities are included in other income — net in the Consolidated Statements of Operations and Comprehensive Loss. Unrealized gains and losses, net of deferred taxes, on available-for-sale securities are included in the Consolidated Balance Sheets as a component of accumulated other comprehensive income. Securities classified as available-for-sale are reported as cash and cash equivalent, short-term investments or long-term investments in the Consolidated Balance Sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date. The Company’s debt securities are primarily comprised of U.S. government securities, treasury bills, commercial paper, corporate securities, and money markets. These available-for-sale investments are held in the custody of a major financial institution. Other-than-Temporary Impairments on Investment The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2019 and 2018, there was no impairment of the Company’s investments. Accounts Receivable Accounts receivable represents amounts owed to the Company from product sales, licenses and contract research and government grants. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had no amounts reserved for doubtful accounts at December 31, 2019 and 2018 as the Company expected full collections of all accounts receivable balances as of each of these dates. Inventory GoodWheat: Propriety wheat plants are grown, producing seed with a variety of improved nutritional qualities, including high levels of amylose, improved shelf-life, and reduced gluten. This seed is used for subsequent plantings or processed, and sold as GoodWheat seeds, grain, and flour, which we refer to collectively as our GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process and store harvested seed and grain, and costs to mill the grain into flour. SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil: Proprietary safflower plants are grown, producing seed with a high-GLA content. This seed is used for subsequent plantings or processed, and sold as GLA oil, including SONOVA 400 GLA safflower oils and SONOVA Ultra GLA safflower oil, which we refer to collectively as our SONOVA products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops and costs to process and store harvested seed. Hemp seeds are procured for the purpose of planting, harvesting, and extracting CBD oil to eventually be sold. Amounts inventories consist primarily of fees paid to suppliers to obtain the seeds. Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write downs to inventory are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded $304,000 and $310,000 of inventory write-downs for the years ended December 31, 2019 and 2018, respectively. The inventories—current line item on the balance sheet consists of the cost of GoodWheat seed, grain, and flour, GLA oil, and hemp seed inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date. The inventories—noncurrent line item consists of GLA oil and seed inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date. Raw materials inventories consist primarily of the cost of hemp seeds and GLA seed production costs incurred by our contracted cooperators. Goods in process inventories consist of costs to process hemp seed and GoodWheat seed and grain. Finished goods inventories consist of GoodWheat products and GLA oil that are available for sale. Inventories, net consist of the following (in thousands): As of December 31, 2019 2018 Raw Materials $ 67 $ 41 Goods in process 188 — Finished Goods 1,903 886 Inventories, net $ 2,158 $ 927 Property and Equipment Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2-20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2-10 * * Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease. Impairment of Long-Lived Assets The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. As of December 31, 2019 and 2018, there was no impairment of the Company’s long-lived assets. Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and notes payable approximated their fair values due to the short period of time to maturity or repayment. Concentration of Risk Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties. Customer Concentration Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. The Company had three customers that represented 47%, 17%, and 15% of accounts receivable, and three customers that represented 44%, 34%, and 13% of accounts receivable, as of December 31, 2019 and 2018, respectively. The Company had two customers that represented 40% and 15% of total revenues, and four customers that represented 19%, 16%, 13%, and 11% of total revenues, for the years ended December 31, 2019 and 2018, respectively. Stock-Based Compensation The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 12 for additional information. Amounts recognized in the Consolidated Statements of Operations and Comprehensive Loss were as follows (in thousands): Year Ended December 31, 2019 2018 (in thousands) Research and development $ 321 $ 379 Selling, general and administrative 1,966 1,171 Total stock-based compensation $ 2,287 $ 1,550 Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. Net Loss per Share Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses. Revenue Recognition We derive our revenues from product revenues, licensing agreements, royalties, contract research agreements, and government grants. Product Revenues Our product revenues to date have consisted primarily of sales of our SONOVA products, with initial GoodWheat seed sale revenues recognized in the fourth quarter of 2019. We recognize revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively “our customers,” which generally occurs upon shipment. Our revenues fluctuate depending on the timing of shipments of product to our customers. License Revenues Our license revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that we receive under our research and license agreements. We recognize revenue generated from up-front, nonrefundable license fees upon execution of the agreement. We recognize annual license fees when it is probable that a material reversal will not occur. Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees Contract Research Revenues Contract research and government grant revenues consist of amounts earned from performing contracted research primarily related to breeding programs or the genetic engineering of plants for third parties. Contract research revenue is accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g. costs incurred to date relative to the total estimated costs at completion). Government Grant Revenues The Company receives payments from government entities in the form of government grants. Government grant revenue is accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g. costs incurred to date relative to the total estimated costs at completion). The Company’s obligation with respect to these agreements is to perform the research on a best-efforts basis. Unearned Revenue The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies. During the year ended December 31, 2019, we recognized revenue of $96,000 that was included in unearned revenue on the consolidated balance sheet as of December 31, 2018. Cost of Product Revenues Cost of product revenues relates to the sale of our SONOVA and GoodWheat products and consists of in-licensing and royalty fees, any adjustments or write-downs to inventory, as well as the cost of raw materials, including inventory and third-party services costs related to procuring, processing, formulating, packaging, and shipping our products. Research and Development Expenses Research and development expenses consist of costs incurred in the discovery, development, and testing of our products and products in development incorporating our traits. These expenses consist primarily of employee salaries and benefits, fees paid to subcontracted research providers, fees associated with in-licensing technology, land leased for field trials, chemicals and supplies, and other external expenses. These costs are expensed as incurred. Additionally, as disclosed in Note 13, the Company is required from time to time to make certain milestone payments in connection with the development of technologies in-licensed from third parties. These milestone payments are expensed at the time the milestone is achieved and deemed payable. C hange in Fair Value of Contingent Consideration Change in the fair value of contingent consideration is comprised of the gain associated with the reduction of our contingent liability. See Note 13. C hange in the Estimated Fair Value of Common Stock Warrant Liabilities and Common Stock Adjustment Feature Liability Change in the estimated fair value of common stock warrant liabilities and common stock adjustment feature liability is comprised of the fair value remeasurement of the liabilities associated with the March 2018 Private Placement and the June 2018, June 2019, and September 2019 Offerings. See Note 11.

Recent Accounting Pronouncement

Recent Accounting Pronouncements	12 Months Ended
	Dec. 31, 2019
Accounting Changes And Error Corrections [Abstract]
Recent Accounting Pronouncements	Note 3. Recent Accounting Pronouncements In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU No. 2016-02, Leases (Topic 842) In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments Codification Improvements to Topic 326, Financial Instruments — Credit Losses (Topic 326) — Targeted Transition Relief, In August 2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement The Company is currently evaluating the adoption of ASU No. 2018-13, and expects that the disclosures regarding measurement of Level 3 fair value instruments will be expanded. In June 2018, the FASB issued ASU No. 2018-07, Compensation—Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Equity – Equity Based Payments to Non-Employees In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. The amendments are effective for all entities for fiscal years beginning after December 15, 2020.

Property and Equipment, Net

Property and Equipment, Net	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Property and Equipment, Net	Note 4. Property and Equipment, Net Property and equipment, net consisted of the following (in thousands): As of December 31, 2019 2018 Laboratory equipment $ 2,443 $ 2,348 Software and computer equipment 502 477 Machinery and equipment 989 — Furniture and fixtures 90 85 Vehicles 395 204 Leasehold improvements 2,023 2,082 Property and equipment, gross 6,442 5,196 Less accumulated depreciation and amortization (4,643 ) (4,801 ) Property and equipment, net $ 1,799 $ 395 Depreciation expense was $194,000 and $154,000 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019 and 2018, respectively, there was $1,014,000 and $10,000 of construction in progress included in property and equipment that had not been placed into service and was not subject to depreciation.

Investments and Fair Value Meas

Investments and Fair Value Measurements	12 Months Ended
	Dec. 31, 2019
Investments And Fair Value Measurements [Abstract]
Investments and Fair Value Measurements	Note 5. Investments and Fair Value Measurements Available-for-Sale Investments The Company classified short-term investments as “available-for-sale.” These short-term investments are free of trading restrictions. The investments are carried at fair value, based on quoted market prices or other readily available market information. Unrealized gains and losses, net of taxes, are included in accumulated other comprehensive loss, which is reflected as a separate component of stockholder’s equity in the Consolidated Balance Sheets. Gains and losses are recognized when realized in the Consolidated Statements of Operations and Comprehensive Loss. The following tables summarize the amortized cost and fair value of the available-for-sale investment securities portfolio at December 31, 2019 and December 31, 2018, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2019 Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper 900 — — 900 Short-term investments: Corporate securities 3,300 — — 3,300 Treasury bills 1,495 1 — 1,496 Commercial paper 12,119 — — 12,119 Total Assets at Fair Value $ 24,678 $ 1 $ — $ 24,679 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2018 Cash equivalents: Money market funds $ 9,902 $ — $ — $ 9,902 Commercial paper 1,345 — — 1,345 Short-term investments: Corporate securities 656 — — 656 Treasury bills 1,195 — — 1,195 Commercial paper 6,776 — — 6,776 U.S. government securities 1,198 — — 1,198 Total Assets at Fair Value $ 21,072 $ — $ — $ 21,072 The Company did not have any investment categories that were in a continuous unrealized loss position for more than twelve months as of December 31, 2019. Fair Value Measurement The fair value of the available-for-sale investments at December 31, 2019 were as follows: Fair Value Measurements at December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper — 900 — 900 Short-term investments: Corporate securities — 3,300 — 3,300 Treasury bills 1,496 — — 1,496 Commercial paper — 12,119 — 12,119 Total Assets at Fair Value $ 8,360 $ 16,319 $ — $ 24,679 The fair value of the available-for-sale investments at December 31, 2018 were as follows: Fair Value Measurements at December 31, 2018 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 9,902 $ — $ — $ 9,902 Commercial paper — 1,345 — 1,345 Short-term investments: Corporate securities — 656 — 656 Treasury bills 1,195 — — 1,195 Commercial paper — 6,776 — 6,776 U.S. government securities 1,198 — — 1,198 Total Assets at Fair Value $ 12,295 $ 8,777 $ — $ 21,072 The Company uses the market approach technique to value its financial instruments and there were no changes in valuation techniques during 2019 or 2018. The Company’s financial instruments consist primarily of cash and cash equivalents, accounts receivable, accounts payable, accrued liabilities, and notes payable. For accounts receivable, accounts payable, accrued liabilities, and notes payable the carrying amounts of these financial instruments as of December 31, 2019 and 2018 were considered representative of their fair values due to their short term to maturity or repayment. Cash equivalents are carried at cost, which approximates their fair value. The Company’s Level 3 liabilities consist of a contingent liability resulting from the Anawah acquisition, as described in Note 13, and liabilities related to the March 2018 Purchase Agreement, the June 2018 Offering, the June 2019 Offering and the September 2019 Offering described in Note 11 (the “warrant liabilities”). The contingent liability was measured and recorded on a recurring basis as of December 31, 2019 and 2018 using unobservable inputs, namely the Company’s ability and intent to pursue certain specific products developed using technology acquired in the purchase T he warrant liabilities were measured and recorded on a recurring basis Assumptions: Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Common Stock Warrant Liability - June 2019 Offering Common Stock Warrant Liability - September 2019 Offering Stock price $ 5.48 $ 5.48 $ 5.48 $ 5.48 Expected term (years) 3.22 3.96 4.96 5.20 Expected volatility 125% 123% 120% 120% Risk-free interest rate 1.63% 1.65% 1.69% 1.70% Expected dividend yield — — — — The warrant liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions as of December 31, 2018: Assumptions: Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Stock price $ 3.17 $ 3.17 Expected term (years) 4.22 4.96 Expected volatility 110% 105% Risk-free interest rate 2.49% 2.50% Expected dividend yield — — The significant unobservable input used in the fair value measurement of the Company’s Level 3 warrant liabilities is volatility. A significant increase (decrease) in volatility could result in a significantly lower (higher) fair value measurement. The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Adjustment Feature Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Common Stock Warrant Liability - June 2019 Offering Common Stock Warrant Liability - September 2019 Offering Contingent Liability Total Balance as of December 31, 2017 $ — $ — $ — $ — $ — $ 3,000 $ 3,000 Common stock and warrants issued in conjunction with March 2018 Offering 10,200 3,800 — — — — $ 14,000 Common stock and warrants issued in conjunction with June 2018 Offering — — 9,022 — — — $ 9,022 Change in fair value and other adjustments (7,846 ) 4,578 (6,293 ) — — — $ (9,561 ) Reclassification of common stock adjustment feature liability balance to equity — (8,378 ) — — — — $ (8,378 ) Balance as of December 31, 2018 2,354 — 2,729 — — 3,000 $ 8,083 Common stock and warrants issued in conjunction with June 2019 Offering — — — 4,198 — — $ 4,198 Common stock and warrants issued in conjunction with September 2019 Offering — — — — 3,428 — $ 3,428 Change in fair value and other adjustments 2,225 — 2,715 4,811 (508 ) (1,000 ) $ 8,243 Exercise of warrants — — — (7,016 ) — — $ (7,016 ) Balance as of December 31, 2019 $ 4,579 $ — $ 5,444 $ 1,993 $ 2,920 $ 2,000 $ 16,936

Consolidated Joint Venture

Consolidated Joint Venture	12 Months Ended
	Dec. 31, 2019
Equity Method Investments And Joint Ventures [Abstract]
Consolidated Joint Venture	Note 6. On August 9, 2019, the Company and Legacy Ventures Hawaii, LLC, a Nevada limited liability company (“Legacy”), formed Archipelago Ventures Hawaii, LLC, a Delaware limited liability company and entered into a Limited Liability Company Operating Agreement (the “Operating Agreement”). The Company and Legacy formed Archipelago to develop, extract and commercialize hemp-derived products from industrial hemp grown in Hawaii. Pursuant to the Operating Agreement, a joint operating committee consisting of two individuals appointed by the Company and two individuals appointed by Legacy will manage Archipelago. As of December 31, 2019, the Company and Legacy hold 50.75% and 49.25% interests in Archipelago, respectively, and have made capital contributions to Archipelago of $709,000 and $689,000, respectively, as determined by the joint operating committee. The Operating Agreement includes indemnification rights, non-competition obligations, and certain rights and obligations in connection with the transfer of membership interests, including rights of first refusal. We consolidate Archipelago in the consolidated financial statements after eliminating intercompany transactions. Net loss attributable to non-controlling interest of $68,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the year ended December 31, 2019. Legacy’s equity interests are presented as non-controlling interests on the Consolidated Balance Sheets. Refer to Note 2 for basis of presentation.

Variable Interest Entity

Variable Interest Entity	12 Months Ended
	Dec. 31, 2019
Equity Method Investments And Joint Ventures [Abstract]
Variable Interest Entity	Note 7. Variable Interest Entity In February 2012, the Company formed Verdeca LLC (“Verdeca”), which is equally owned with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative owned by approximately 300 shareholders, including some of South America’s largest soybean growers. Verdeca was formed to develop and deregulate soybean varieties using both partners’ agricultural technologies. Both the Company and Bioceres incur expenses in support of specific activities agreed, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0 million in the aggregate over a four-year period. The Company determined that its commitment to purchase common stock in Bioceres, S.A. as a means to provide capital to Verdeca resulted in a de facto agency relationship between the Company and Bioceres. The Company considers qualitative factors in assessing the primary beneficiary which include understanding the purpose and design of the VIE, associated risks that the VIE creates, activities that could be directed by the Company, and the expected relative impact of those activities on the economic performance of the VIE. Based on an evaluation of these factors, the Company concluded that it is the primary beneficiary of Verdeca. Under the terms of the joint development agreement, the Company has incurred direct expenses and allocated overhead in the amount of $559,000 and $947,000 for the years ended December 31, 2019 and 2018, respectively.

Accounts Payable and Accrued Ex

Accounts Payable and Accrued Expenses	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Accounts Payable and Accrued Expenses	Note 8. Accounts Payable and Accrued Expenses Accounts payable and accrued expenses consisted of the following (in thousands): As of December 31, 2019 2018 Accounts payable - trade $ 492 $ 285 Payroll and benefits 1,290 1,096 Inventory 1,143 — Research and development 629 433 Royalty fees due to unrelated parties 226 187 Consulting 397 92 Rent and utilities 23 91 Audit and tax fees 113 23 Legal 138 285 Other 234 153 Total accounts payable and accrued expenses $ 4,685 $ 2,645

Collaborative Arrangements

Collaborative Arrangements	12 Months Ended
	Dec. 31, 2019
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Collaborative Arrangements	Note 9. Collaborative Arrangements In August 2017, the Company entered into a collaborative arrangement for the research, development and commercialization of an improved wheat quality trait in North America. This collaborative arrangement is a contractual agreement with Corteva Agriscience (“Corteva”) involves a joint operating activity where both Arcadia and Corteva are active participants in the activities of the collaboration. Arcadia and Corteva participate in the research and development, and Arcadia has the primary responsibility for the intellectual property strategy while Corteva will generally lead the marketing and commercialization efforts. Both parties are exposed to significant risks and rewards of the collaboration and the agreement includes both cost sharing and profit sharing. The activities are performed with no guarantee of either technological or commercial success. The Company accounts for research and development (“R&D”) costs in accordance ASC 730, Research and Development

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Notes Payable	Note 10. Notes Payable During the year ended December 31, 2019, the Company entered into notes payable agreements to finance the purchase of company vehicles. These notes have an interest rate of 8%, term of five years, and mature in 2024. There were no notes payable as of December 31, 2018. Maturities of notes payable as of December 31, 2019 are as follows (in thousands): Years Ending December 31, Amounts 2020 $ 24 2021 27 2022 29 2023 31 2024 20 Total notes payable $ 131 Less: current portion 24 Notes payable - noncurrent $ 107

Private Placement and Registere

Private Placement and Registered Direct Offerings	12 Months Ended
	Dec. 31, 2019
Warrants And Rights Note Disclosure [Abstract]
Private Placement and Registered Direct Offerings Disclosure	Note 11. Private Placement and Registered Direct Offerings Private Placement (2018) On March 22, 2018, the Company issued 300,752 shares of its common stock (“Common Stock”) and warrants to purchase up to 300,752 shares of Common Stock with an initial exercise price equal to $45.75 (the “March 2018 Warrants”), in a private placement (the “March 2018 Private Placement”) in accordance with a securities purchase agreement (the “March 2018 Purchase Agreement”) entered into with certain institutional and accredited investors (collectively, the “Purchasers”) on March 19, 2018. The March 2018 Warrants are immediately exercisable, subject to certain ownership limitations, and expire five years after the date of issuance. The per share purchase price of the Common Stock and per share exercise price for the March 2018 Warrants were subject to adjustment based on the volume weighted average price for the three trading days (the “VWAP Calculation”) after each of the following: (i) the date that a registration statement covering the resale of the securities being issued in the March 2018 Private Placement (“March 2018 Resale Registration Statement”) has been declared effective by the SEC, (ii) if a registration statement covering all securities issued in the March 2018 Private Placement is not declared effective, then the date that the securities can be sold under Rule 144 under the Securities Act of 1933, as amended, and (iii) if later than the dates set forth in item (i) and (ii), then the date that the Company’s shareholders approve the March 2018 Private Placement. After each adjustment, the per share purchase price for Common Stock was automatically reduced to 80% of the VWAP Calculation, and the per share exercise price for the March 2018 Warrant was automatically reduced, to 110% of the VWAP Calculation; provided, that in no event, will the per share purchase price for the Common Stock or the exercise price for the March 2018 Warrants be less than $8.322. Upon any adjustment of the per share exercise price for the March 2018 Warrants, then the number of shares exercisable under the March 2018 Warrants would be increased so that the aggregate exercise price payable after adjustment was equal to the aggregate exercise price payable prior to such adjustment. The Company filed the March 2018 Resale Registration Statement with the SEC on March 30, 2018, and it was declared effective on April 23, 2018. As described above and based upon the applicable VWAP Calculations relating to these events, each of these events caused an adjustment to the number of shares issued in the March 2018 Private Placement and underlying the March 2018 Warrants. Following the effectiveness of the March 2018 Resale Registration Statement, on April 23, 2018 the number of shares issued pursuant to the March 2018 Purchase Agreement increased from 300,752 to 798,754, the total number of shares issuable upon exercise of the March 2018 Warrants increased from 300,752 to 799,300 and the per share exercise price of the March 2018 Warrants reduced from $45.75 to $17.2143. The Company held a special meeting of its shareholders on May 2, 2018 and obtained shareholder approval for the issuance of Common Stock in the March 2018 Private Placement. Following shareholder approval of the issuance of shares in the March 2018 Private Placement, on May 8, 2018 the number of shares issued pursuant to the March 2018 Purchase Agreement increased from 798,754 to 1,201,634, the total number of shares issuable upon exercise of the Warrants increased from 799,300 to 1,282,832 and the per share exercise price of the March 2018 Warrants reduced from $17.2143 to $10.7258. The aggregate net proceeds received by the Company from the March 2018 Private Placement was $8.7 million, consisting of gross proceeds of $10.0 million less offering costs of $1.3 million. The adjustment feature for the Common Stock and the March 2018 Warrants were determined to be liabilities based on each instrument’s adjustment features and the contingent cash payment feature of the common stock warrants. The liabilities were accounted for at their respective fair values at inception using a Monte Carlo simulation model with the following assumptions: volatility of 100%, stock price of $32.52 and risk-free rate of 2.63%. At inception, the fair values of the Common Stock adjustment feature and the March 2018 Warrant liabilities were $3.8 million and $10.2 million, respectively. As the combined value of the liabilities exceeded the $10.0 million of proceeds, no value was assigned to the Common Stock issued and an initial loss of $4.0 million was recognized. In May 2018, following the March 2018 Private Placement’s final adjustment, the terms of the March 2018 Warrants and the number of Common Stock shares issuable in the March 2018 Private Placement became known and fixed. As a result, the Common Stock adjustment feature liability was marked-to-market and valued at $8.4 million at May 7, 2018, resulting in an additional loss of $2.4 million recognized in the second quarter of 2018. The Company subsequently reclassified the Common Stock adjustment feature liability’s balance of $8.4 million to stockholders’ equity. The March 2018 Warrant liability was marked-to-market and valued at $2.4 million at December 31, 2018, resulting in income of $7.9 million recognized throughout the year ended December 31, 2018. The March 2018 Warrant liability was marked-to-market and valued at $4.6 million at December 31, 2019, resulting in expense of $2.2 million recognized throughout the year ended December 31, 2019. Registration Rights Agreement In connection with the March 2018 Private Placement, the Company entered into a registration rights agreement (the “March 2018 Registration Rights Agreement”). Pursuant to the March 2018 Registration Rights Agreement, the Company filed the March 2018 Resale Registration Statement with the SEC on March 30, 2018 for purposes of registering the resale of the shares of Common Stock issued pursuant to the March 2018 Purchase Agreement and the shares of Common Stock issuable upon exercise of the March 2018 Warrants. The SEC declared the registration statement effective on April 23, 2018. Offering Costs In connection with the March 2018 Private Placement, the Company paid to a placement agent an aggregate fee equal to $850,000. The Company also granted warrants to purchase a total of 15,038 shares of Common Stock (the “March 2018 Placement Agent Warrants”) that have an exercise price per share equal to $41.5625 and a term of five years. The March 2018 Placement Agent Warrants were issued for services performed by the placement agent as part of the March 2018 Private Placement and were treated as offering costs. The value of the March 2018 Placement Agent Warrants was determined to be $526,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $458,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the March 2018 Private Placement. The offering costs, inclusive of the March 2018 Placement Agent Warrants, totaled $1.8 million was expensed in the year ended December 31, 2018. Registered Direct Offering (2018) On May 11, 2018, the Company filed a shelf Registration Statement on Form S-3 with the SEC which was declared effective on June 8, 2018. This shelf registration process allows the Company to sell any combination of common stock, preferred stock, warrants and units consisting of such securities in one or more offerings from time to time having an aggregate initial offering price of $50 million. On June 11, 2018, the Company entered into agreements with several institutional and accredited investors (the “June 2018 Purchase Agreement”) for the purchase of 1,392,345 shares of its Common Stock at a purchase price of $9.93 per share for gross proceeds of $13.8 million (the “June 2018 Offering”). The 1,392,345 shares of Common Stock sold in the June Offering were issued pursuant to a prospectus, dated June 8, 2018, and a prospectus supplement dated June 11, 2018, in connection with a takedown from the Company’s shelf Registration Statement on Form S-3. The June Offering closed on June 14, 2018. Additionally, in a concurrent private placement (the “June 2018 Private Placement”), the Company issued to the investors unregistered warrants (the “June 2018 Warrants”) to purchase up to 1,392,345 shares of Common Stock at a purchase price per warrant of $0.125, for gross proceeds of $174,000. The June 2018 Warrants, and the shares of Common Stock underlying the warrants, have an exercise price of $9.94 per share. Subject to certain ownership limitations, the June 2018 W arrants are exercisable upon issuance and expire five and one-half years after the date of issuance. The aggregate net proceeds received by the Company for the June 2018 Offering were $12.8 million, consisting of gross proceeds of $14.0 million less offering costs of $1.2 million. The June June June June June Offering Costs In connection with the June 2018 Offering, the Company paid to a placement agent an aggregate fee equal to $980,000. The Company also granted warrants to purchase a total of 69,617 shares of common stock (“June 2018 Placement Agent Warrants”) that have an exercise price per share equal to $12.568 and a term of five years. The June 2018 Placement Agent Warrants were issued for services performed by the placement agent as part of the June 2018 Offering and were treated as offering costs. The value of the June 2018 Placement Agent Warrants was determined to be $427,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $226,000 that consist of direct incremental legal, advisory, accounting and filing fees relating to the June 2018 Offering. The offering costs, inclusive of the June 2018 Placement Agent Warrants, totaled $1.6 million and allocated to the June 2018 Warrants and the Common Stock using their relative fair values. A total of $721,000 was allocated to the June 2018 Warrants which was expensed during the year ended December 31, 2018. The remaining $912,000 was allocated to the common stock and offset to additional paid in capital. Registration of Warrant Shares (2018) On December 27, 2018, the Company filed a registration statement with the SEC to register for resale 15,038 shares of Common Stock underlying the March 2018 Placement Agent Warrants, 1,392,345 shares of Common Stock underlying the June 2018 Warrants, and 69,617 shares of Common Stock underlying the June 2018 Placement Agent Warrants. This registration statement was declared effective by the SEC on February 15, 2019. Registered Direct Offering (June 2019) On June 12, 2019, the Company entered into a securities purchase agreement with certain institutional and accredited investors (the “June 2019 Purchase Agreement”) relating to the offering and sale of The 1,489,575 shares of Common Stock sold in the June 2019 Offering were issued pursuant to a prospectus, dated June 8, 2018, and a prospectus supplement dated June 12, 2019, in connection with a takedown from the Company’s shelf Registration Statement on Form S-3. The June 2019 Offering closed on June 14, 2019. Additionally, in a concurrent private placement (the “June 2019 Private Placement”), the Company issued to the investors unregistered warrants to purchase up to 1,489,575 shares of Common Stock at a purchase price per warrant of $0.125, for gross proceeds of $186,000 (the “June 2019 Warrants”). The June 2019 Warrants, and the shares of Common Stock underlying the June 2019 Warrants have an exercise price of $5.00 per share. Subject to certain ownership limitations, the June 2019 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance. The aggregate net proceeds received by the Company for the June 2019 Offering were $6.8 million, consisting of gross proceeds of $7.5 million less offering costs of $663,000. The June 2019 Warrants June 2019 Warrants In August and September 2019, investors exercised 1,053,745 warrants, generating cash proceeds totaling $5.3 million. The June 2019 Warrants were marked-to-market at the time of exercise and valued at $9.9 million, resulting in expense recognized of $6.5 million. Of the $9.9 million warrant liability balance, $7.0 million was allocated to the exercised warrants and reclassified to stockholders’ equity with the remaining $2.9 million attributed to the unexercised warrants. June Offering Costs In connection with the June 2019 Offering, the Company paid to a placement agent an aggregate fee equal to $525,000. The Company also granted warrants to purchase a total of 74,479 shares of Common Stock (“June 2019 Placement Agent Warrants”) that have an exercise price per share equal to $6.2938 and a term of five years. The June 2019 Placement Agent Warrants were issued for services performed by the placement agent as part of the June 2019 Offering and were treated as offering costs. The value of the June 2019 Placement Agent Warrants was determined to be $198,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $115,000 that consist of direct incremental legal, advisory and filing fees relating to the June 2019 Offering. The offering costs, inclusive of the June 2019 Placement Agent Warrants, totaled $0.9 million and were allocated to the June 2019 Warrants and the Common Stock using their relative fair values. A total of $377,000 was allocated to the June 2019 Warrants which was expensed during the year ended December 31, 2018. The remaining $489,000 was allocated to the common stock and offset to additional paid in capital. Registered Direct Offering (September 2019) On September 5, 2019, the Company entered into a securities purchase agreement with certain institutional and accredited investors (the “September 2019 Purchase Agreement”) relating to the offering and sale of September The 1,318,828 shares of Common Stock sold in the September 2019 Offering were issued pursuant to a prospectus, dated June 8, 2018, and a prospectus supplement dated September 5, 2019, in connection with a takedown from the Company’s shelf Registration Statement on Form S-3. The September 2019 Offering closed on September 10, 2019. Additionally, in a concurrent private placement (the “ 2019 Private Placement”), the Company issued to the investors unregistered warrants to purchase up to 659,414 shares of Common Stock at a purchase price per warrant of $0.125, for gross proceeds of $82,000 (the “ 2019 Warrants”). The 2019 Warrants, and the shares of Common Stock underlying the 2019 warrants have an exercise price of $7.52 per share. Subject to certain ownership limitations, the September 2019 Warrants are exercisable upon issuance and expire five and one-half years after the date of issuance. The aggregate net proceeds received by the Company for the September The September 2019 Warrants September 2019 Warrants September September 2019 Warrants Offering Costs In connection with the September 2019 Offering, the Company paid to a placement agent an aggregate fee equal to $700,000. The Company also granted warrants to purchase a total of 65,942 shares of common stock (“September 2019 Placement Agent Warrants”) that have an exercise price per share equal to $9.4781 and a term of five years. The September 2019 Placement Agent Warrants were issued for services performed by the placement agent as part of the September 2019 Offering and were treated as offering costs. The value of the September 2019 Placement Agent Warrants was determined to be $326,000 using the Black-Scholes Model with input assumptions including the Company’s stock price, expected life of the warrants, stock price volatility determined from the Company’s historical stock prices and the volatility of a peer group, and the risk-free interest rate for the term of the warrants. The Company incurred additional offering costs totaling $113,000 that consist of direct incremental legal, advisory and filing fees relating to the September 2019 Offering. The offering costs, inclusive of the September 2019 Placement Agent Warrants, totaled $1.1 million and were allocated to the September 2019 Warrants and the Common Stock using their relative fair values. A total of $331,000 was allocated to the September 2019 Warrants which was expensed during the year ended December 31, 2019. The remaining $808,000 was allocated to the common stock and offset to additional paid in capital. Registration of Warrant Shares (2019) On August 21, 2019, the Company filed a registration statement with the SEC to register for resale 1,489,575 shares of Common Stock underlying the June 2019 Warrants and 74,479 shares of Common Stock underlying the June 2019 Placement Agent Warrants. The registration statement was declared effective by the SEC on August 27, 2019. On December 11, 2019, the Company filed a registration statement with the SEC to register for resale 659,414 shares of Common Stock underlying the September 2019 Warrants and 65,942 shares of Common Stock underlying the September 2019 Placement Agent Warrants. The registration statement was declared effective by the SEC on December 20, 2019.

Stock-Based Compensation and Wa

Stock-Based Compensation and Warrants	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Share Based Payments And Warrants [Abstract]
Stock-Based Compensation and Warrants	Note 12. Stock-Based Compensation and Warrants Stock Incentive Plans The Company has two equity incentive plans: the 2006 Stock Plan (“2006 Plan”) and the 2015 Omnibus Equity Incentive Plan (“2015 Plan”). In 2006, the Company adopted the 2006 Plan, which provided for the granting of stock options to executives, employees, and other service providers under terms and provisions established by the Board of Directors. The Company granted non-statutory stock options (“NSOs”) under the 2006 Plan until May 2015, when it was terminated as to future awards, although it continues to govern the terms of options that remain outstanding and were issued under the 2006 Plan. The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan. The 2015 Plan provides for the grant of incentive stock options (“ISOs”), NSOs, restricted stock awards, stock units, stock appreciation rights, and other forms of equity compensation, all of which may be granted to employees, officers, non-employee directors, and consultants. The ISOs and NSOs will be granted at a price per share not less than the fair value at the date of grant. Options granted generally vest over a four-year period; however, the options granted in the third quarter of 2018 vest over two-year period, vesting monthly on a pro-rated basis. Options granted, once vested, are generally exercisable for up to 10 years, after grant. In June 2019, the shareholders approved an amendment to the Company’s 2015 Plan for a one-time increase to the number of shares of common stock that may be issued under the 2015 Plan by 120,000 shares. As of December 31, 2019, a total of 675,340 shares of common stock were reserved for issuance under the 2015 Plan, of which 58,868 shares of common stock are available for future grant. As of December 31, 2019, a total of 45,229 and 616,472 options are outstanding under the 2006 and 2015 Plans, respectively. The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2017 288,129 $ 63.62 $ — Options granted 302,077 6.65 Options exercised (44,354 ) 21.73 Options forfeited (4,006 ) 14.21 Options expired (11,802 ) 43.73 Outstanding — Balance at December 31, 2018 530,044 35.53 $ — Options granted 208,571 5.13 Options exercised (546 ) 4.63 Options forfeited (30,132 ) 33.95 Options expired (46,236 ) 98.69 Outstanding — Balance at December 31, 2019 661,701 21.60 $ 305 Vested and expected to vest — December 31, 2019 654,170 21.74 $ 301 Exercisable —December 31, 2019 410,270 $ 29.24 $ 192 Aggregate intrinsic value represents the difference between the exercise price of the options and the estimated fair value of the Company’s common stock determined by our Board of Directors for each of the respective periods. The intrinsic value of options exercised was At December 31, 2019 and 2018, the total grant-date fair value of shares vested during the years was $2.2 million and $1.3 million, respectively. As On August 22, 2019, Rajendra Ketkar provided notice to the Company of his retirement as Arcadia’s president, chief executive officer and director, effective as of September 1, 2019. On August 23, 2019, Arcadia and Mr. Ketkar entered into a Separation and Release Agreement (the “Separation Agreement”) which provides that the vesting of certain options previously issued to Mr. Ketkar will be accelerated pursuant to the terms of the Separation Agreement. In addition, the Separation Agreement extends the post-termination exercise period of the accelerated options from 90 days to up to two years. The stock compensation expense related to the modification of Mr. Ketkar’s stock options was $438,000 and recognized in selling, general and administrative expenses during the year ended December 31, 2019. In determining the fair value of the stock-based awards, the Company uses the Black-Scholes option-pricing model and assumptions discussed below. Each of these inputs is subjective and generally requires significant judgment to determine. Expected T The expected term is the estimated period of time outstanding for stock options granted and was estimated based on a simplified method allowed by the SEC due to insufficient historical data, and defines the term as the average of the contractual term of the options and the weighted-average vesting period for all open employee awards. Expected V Since the Company was privately held and does not have a long trading history for its common stock, the expected volatility was estimated based on the average volatility for comparable publicly traded biotechnology companies over a period equal to the expected term of the stock option grants. When selecting comparable publicly traded biotechnology companies on which it has based its expected stock price volatility, the Company selected companies with comparable characteristics to it, including enterprise value, risk profiles, position within the industry, and with historical share price information sufficient to meet the expected life of the stock-based awards. The historical volatility data was computed using the daily closing prices for the selected companies’ shares during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available. Ris k F The risk-free interest rate is based on the interest rate of U.S. Treasuries of comparable maturities on the date the options were granted. Expected The expected dividend yield is based on the Company’s expectation of future dividend payouts to common stockholders. The Year Ended December 31, Assumptions 2019 2018 Expected term (years) 7.04 5.99 Expected volatility 99% 99% Risk-free interest rate 2.01% 2.95% Expected dividend yield — — The Employee Stock Purchase Plan The Company’s 2015 Employee Stock Purchase Plan (“ESPP”) became effective on May 14, 2015. The ESPP allows eligible employees to purchase shares of the Company’s common stock at a discount of up to 15% of their eligible compensation through payroll deductions, subject to any plan limitations. After the first offering period, which began on May 14, 2015 and ended on February 1, 2016, the ESPP provides for six-month offering periods, and at the end of each offering period, employees are able to purchase shares at 85% of the lower of the fair market value of the Company’s common stock on the first trading day of the offering period or on the last day of the offering period. As of December 31, 2019, the number of shares of common stock reserved for future issuance under the ESPP is 102,828. The ESPP provides for automatic annual increases in the shares available for purchase beginning on January 1, 2016. As of December 31, 2019, 15,389 shares had been issued under the ESPP. The Company recorded $16,000 and $11,000 of ESPP related compensation expense for the years ended December 31, 2019 and 2018, respectively. Warrants As of December 31, 2019, the Company had 4,170,651 common stock warrants outstanding with a weighted average exercise price of $9.18. The expiration of the warrants ranges from July 2020 to March 2025. On December 2013, the Company issued warrants to Mahyco International to purchase 3,784 shares of common stock, exercisable as of the issuance date, at an exercise price of $330.40 per share. These warrants expired on December 11, 2018. In connection with the Series D preferred stock financing in the first half of 2014, the Company issued warrants, exercisable as of the issuance date, to the Series D preferred stock investors to purchase an aggregate of 61,397 shares of common stock at an exercise price of $363.20 per share and to the placement agents to purchase 1,674 shares of common stock at $268.80. These warrants expired during the year ended December 31, 2019. As of December 31, 2019, 1,297,870 common stock warrants that were issued in the March 2018 Private Placement are outstanding. Of the total, 1,282,832 shares have a purchase price of $10.7258 and the remaining 15,038 common stock warrants have an exercise price of $41.5625. See Note 11. As of December 31, 2019, 1,461,962 common stock warrants that were issued in the June 2018 Offering are outstanding. Of the total, 1,392,345 shares have a purchase price of $9.94 and the remaining 69,617 common stock warrants have an exercise price of $12.568. See Note 11. In connection with a professional services agreement with a non-affiliated third party, executed in April 2019, the Company issued 45,154 warrants (“Service Warrants”) at an exercise price of $6.18. The Service Warrants vest ratably over 12 months and expire in five years from the date of issuance. The Service Warrants are cancelable immediately prior to a change of control subsequent to the termination/expiration of the advisory agreement. The Company also issued 100,000 performance-based warrants (“Performance Warrants”) at an exercise price of $6.18 and vest in 1/6 increments upon the achievement of a qualifying milestone as defined within the agreement. The Performance Warrants expire in five years from the date of issuance and are cancelable immediately prior to a change of control subsequent to the sixth month anniversary of the termination/expiration of the advisory agreement. The Service and Performance Warrants Service and Performance Warrants As of December 31, 2019, 510,309 common stock warrants that were issued in the June 2019 Offering are outstanding. Of the total, 435,830 shares have a purchase price of $5.00 and the remaining 74,479 common stock warrants have an exercise price of $6.2938. See Note 11. As of December 31, 2019, 725,356 common stock warrants that were issued in the September 2019 Offering are outstanding. Of the total, 659,414 shares have a purchase price of $7.52 and the remaining 65,942 common stock warrants have an exercise price of $9.4781. See Note 11.

Commitment and Contingencies

Commitment and Contingencies	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 13. Commitments and Contingencies Notes Payable During the year ended December 31, 2019, the Company entered into notes payable agreements to finance the purchase of company vehicles. See Note 10. Leases The Company leases office and laboratory space, greenhouse space, grain storage bins, warehouse space, farmland, and equipment under operating lease agreements having initial lease terms ranging from one to five years, including certain renewal options available to the Company at market rates. The Company also leases land for field trials on a short-term basis. See Note 14. Legal Matters From time to time, in the ordinary course of business, the Company may become involved in certain legal proceedings. Except as set forth below, we currently are not a party to any material litigation or other material legal proceedings. In February 2018, we initiated an interference proceeding with the United States Patent and Trademark Office (“USPTO”) concerning a patent application owned by us and a patent owned by Arista Cereals Technologies Pty Limited (“Arista”) relating to our Resistant Starch Wheat products to determine priority of invention. On August 14, 2018, the USPTO issued a decision that resulted in termination of the interference which we appealed. On August 9, 2019, the United States Court of Appeals for the Federal Circuit upheld the decision. Based on this decision, our patent interference proceeding is now terminated, and Arista maintains its patent. On April 1, 2019, Arista and Bay State Milling Company (“BSM”) filed a Complaint against us in the United States District Court for the District of Delaware, asserting claims for alleged patent infringement (“the Delaware Action”). On June 26, 2019 the Court issued a Joint Stipulation and Order to Extend Time to Serve Summons and Complaint until October 15, 2019 indicating that “the parties have agreed on this stipulation seeking additional time…in light of the ongoing settlement discussions between the parties and the desire to preserve the litigation status quo for a short period of time in order to enable continuing settlement discussions.” On April 24, 2019, Arista initiated an interference proceeding with the USPTO concerning the same patent relating to our Resistant Starch Wheat products (U.S. 10,246,716) to determine the priority of invention (“the 716 Interference”). If the USPTO determined Arista was the first to invent, the subject matter of the interference would be granted in a patent to Arista. On the other hand, if the USPTO determined we were the first to invent, we would maintain our patent. On August 21, 2019, we entered into a binding term sheet with Arista and BSM to resolve the parties’ disputes, including the Delaware Action and the 716 Interference. Under the binding term sheet, BSM will become the exclusive commercial partner for our high fiber wheat in North America under Bay State Milling’s HealthSense™ brand portfolio, while Arista receives exclusive rights under our high fiber wheat intellectual property in certain geographies, including Australia and Europe. We will continue to market our high fiber wheat under our GoodWheat portfolio of specialty wheat ingredients in other international markets. In December 2019, the three parties entered into a settlement agreement reflecting the terms of the binding term sheet. Contingent Liability Related to the Anawah Acquisition On June 15, 2005, the Company completed its agreement and plan of merger and reorganization with Anawah, Inc. (“Anawah”), to purchase the Anawah’s food and agricultural research company through a non-cash stock purchase. Pursuant to the merger with Anawah, and in accordance with the ASC 805 - Business Combinations, the Company incurred a contingent liability not to exceed $5.0 million. This liability represents amounts to be paid to Anawah’s previous stockholders for cash collected on revenue recognized by the Company upon commercial sale of certain specific products developed using technology acquired in the purchase. As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs thus, the contingent liability was reduced to $3.0 million. During the third quarter of 2016, one of the programs previously accrued for was abandoned and another program previously abandoned was reactivated. During the fourth quarter of 2019, the Company determined that one of the technologies was no longer active and decided to abandon the previously accrued program. As a result, the Company recognized a gain of $1.0 million in the Consolidated Statements of Operations and Comprehensive Loss. As of December 31, 2019, the Company continues to pursue a total of two development programs using this technology and believes that the contingent liability is probable. As a result, $2.0 million remains on the Consolidated Balance Sheet as an other noncurrent liability. Contracts The Company has entered into a non-cancelable service agreement with an unrelated party that requires the Company to pay certain funding commitments. The following table sets forth our minimum funding requirements under this agreement as of December 31, 2019 (in thousands): Years Ending December 31, Amounts 2020 $ 500 2021 750 2022 — 2023 — 2024 — Thereafter — Total $ 1,250 The Company has entered into contract research agreements with unrelated parties that require the Company to pay certain funding commitments. The initial terms of these agreements range from one to three years in duration and in certain cases are cancelable. The Company licenses certain technologies via executed agreements (“In-Licensing Agreements”) that are used to develop and advance the Company’s own technologies. The Company has entered into various In-Licensing Agreements with related and unrelated parties that require the Company to pay certain license fees, royalties, and/or milestone fees. In addition, certain royalty payments ranging from 2% to 15% of net revenue amounts as defined in the In-Licensing Agreements will be due. Royalties due to both related and unrelated parties on license revenue accrued as of December 31, 2019 and 2018 were $266,000 and $216,000, respectively. Royalties are included within research and development on the Consolidated Statements of Operations and Comprehensive Loss. Milestone payments are contingent upon the successful development or implementation of various technologies. Payments for milestones yet to be achieved totaled $2.0 million for both the years ended December 31, 2019 and 2018, respectively. The timing of the payments is not determinable at this time pending research and development currently in progress; however, no payments were made during the years ended December 31, 2019 and 2018. The Company could be adversely affected by certain actions by the government as it relates to government contract revenue received in prior years. Government agencies, such as the Defense Contract Audit Agency routinely audit and investigate government contractors. These agencies review a contractor’s performance under its agreements; cost structure; and compliance with applicable laws, regulations and standards. The agencies also review the adequacy of, and a contractor’s compliance with, its internal control systems and policies, including the contractor’s purchasing, property, estimating, compensation and management information systems. While the Company’s management anticipates no adverse result from an audit, should any costs be found to be improperly allocated to a government agreement, such costs will not be reimbursed, or if already reimbursed, may need to be refunded. If an audit uncovers improper or illegal activities, civil and criminal penalties and administrative sanctions, including termination of contracts, forfeiture of profits, suspension of payments or fines, and suspension or prohibition from doing business with the government could occur. In addition, serious reputational harm or significant adverse financial effects could occur if allegations of impropriety were made against the Company. There currently are routine audits in process relating to government grant revenues.

Leases

Leases	12 Months Ended
	Dec. 31, 2019
Lessee Disclosure [Abstract]
Leases	Note 14. Leases Operating Leases The Company adopted the new lease accounting standards (Topic 842) on January 1, 2019 and used the effective date as our initial application. Prior to January 1, 2019, we accounted for leases in accordance with Topic 840, Leases As of December 31, 2019, the Company leases office space in Davis, CA, Phoenix, AZ, and Molokai, HI, as well as additional buildings, land and equipment. Leases with an initial term of 12 months or less are not recorded on the balance sheet; the Company recognizes lease expense for these leases on a straight-line basis. The Company subleases a portion of the Davis office lease and greenhouse to third parties. As of December 31, 2019, the Company does not currently have any finance leases or material leases that have not yet commenced. Some leases (the Davis office, warehouse, greenhouse and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years. The exercise of lease renewal options is at the Company’s sole discretion. The renewal options were not included in the initial measurement of the ROU assets or operating lease liabilities. During the fourth quarter of 2019, the Company concluded that it was reasonably certain to exercise one of its renewal options. In accordance with ASC 842, the Company accounted for the expected renewal as a lease modification and remeasured the operating lease liability, resulting in an additional $0.2 million right of use asset and operating lease liability. The Company’s lease agreements do not contain any material variable lease payments, material residual value guarantees or material restrictive covenants. Leases consisted of the following (in thousands): Leases Classification December 31, 2019 Assets Operating lease assets Right of use asset $ 1,963 Total leased assets $ 1,963 Liabilities Current - Operating Operating lease liability - current $ 611 Noncurrent - Operating Operating lease liability - noncurrent 1,497 Total leased liabilities $ 2,108 Lease Cost Classification For the Year Ended December 31, 2019 Operating lease cost SG&A and R&D Expenses $ 708 Short term lease cost (1) R&D Expenses 205 Sublease income (2) SG&A and R&D Expenses (55 ) Net lease cost $ 858 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a credit to lease expense. Lease Term and Discount Rate December 31, 2019 Weighted-average remaining lease term (years) 2.6 Weighted-average discount rate 7 % Rent expense recorded under Topic 840 for the year ended December 31, 2018 was $1.3 million. The maturities of our operating lease liabilities as of December 31, 2019 are as follows (in thousands): Years Ending December 31, Amounts 2020 $ 735 2021 681 2022 575 2023 372 Total operating lease payments $ 2,363 Less: imputed interest $ 255 Total current and noncurrent operating lease liabilities $ 2,108

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Note 15. Income Taxes The components of loss before income taxes are as follows (in thousands): Year Ended December 31, 2019 2018 Domestic $ (28,871 ) $ (13,470 ) Foreign — — Loss before income taxes $ (28,871 ) $ (13,470 ) The total income tax expense for the years ended December 31, 2019 and 2018 was $2,000 and $10,000, respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands): Year Ended December 31, 2019 2018 Current: Federal $ — $ — State 2 1 Foreign — 9 Total current tax expense 2 10 Deferred: Federal — — State — — Foreign — — Total deferred tax asset — — Total tax expense $ 2 $ 10 The Company operates in only one federal jurisdiction, the United States. The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2019 2018 Expected income tax provision at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefit 5.3 % 8.5 % Change in valuation allowance (26.4 )% (27.3 )% Transaction costs — (2.9 )% Related offering costs (0.5 )% (1.1 )% Excess windfall benefit — 1.4 % Withholding taxes — (0.1 )% Other 0.6 % 0.4 % Income tax provision — (0.1 )% Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes, net operating loss carryforwards (“NOLs”) and other tax credits. Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands): As of December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 13,267 $ 42,097 Unearned revenue 11 26 Stock-based compensation 3,384 2,855 Accrued payroll and benefits 224 255 Research and development credits — 171 Fixed asset basis difference 90 114 Inventory reserve 568 508 Operating lease liability 565 — Common stock warrant assets 988 — Charitable contributions 2 3 Total deferred tax assets 19,099 46,029 Deferred tax liabilities: Right of use asset (526 ) — Common stock warrant liabilities — (1,529 ) Total deferred tax liabilities (526 ) (1,529 ) Less valuation allowance (18,573 ) (44,500 ) Net deferred tax assets $ — $ — Realization of the deferred tax assets is dependent upon future taxable income, if any, the amount and timing of which are uncertain. Accordingly, the net deferred tax assets have been offset by a valuation allowance. The net valuation allowance decreased by $25.9 million during the year ended December 31, 2019 and increased by $3.2 million during the year ended December 31, 2018. At December 31, 2019, the Company had federal and state NOLs aggregating approximately $186.6 million and $47.9 million, respectively. At December 31, 2019, the utilization of a portion of our federal NOLs is subject to an annual limitation under Section 382 of the Internal Revenue Code (IRC). Of the $186.6 million generated, $7.2 million was previously determined as unavailable to be utilized within the carryforward period, and $130.5 million is expected to be unavailable due to an ownership change under IRC Section 382 that the Company experienced as a result of the common shares issued in connection with the June 2018 Offering. The Company evaluates deferred tax assets, including the benefit from NOLs, to determine if a valuation allowance is required. Such evaluation is based on consideration of all available evidence using a “more likely than not” standard with significant weight being given to evidence that can be objectively verified. This assessment considers, among other matters, the nature, frequency, and severity of current and cumulative losses; forecasts of future profitability; the length of statutory carryforward periods; the Company’s experience with operating losses; and tax-planning alternatives. The significant piece of objective negative evidence evaluated was the cumulative loss incurred through the year ended December 31, 2019. Given this evidence and the expectation to incur operating losses in the foreseeable future, a full valuation allowance has been recorded against the net deferred tax asset. The Company will continue to maintain a full valuation allowance against the entire amount of its net deferred tax asset, until such time as the Company has determined that the weight of the objectively verifiable positive evidence exceeds that of the negative evidence and it is likely that the Company will be able to utilize all of its net deferred tax asset relating to its federal and state NOL carryforwards. Although the Company has established a full valuation allowance on its net deferred tax asset, for Federal tax losses before 2018 and for all state tax losses, it has not forfeited the right to carryforward tax losses up to 20 years and apply such tax losses against taxable income in such years, thereby reducing its future tax obligations. Federal tax losses generated in 2018 and later do not expire. The Company is subject to taxation in the United States and various state jurisdictions. As of December 31, 2019, the Company’s tax years for 2000 through 2019 are generally subject to examination by the tax authorities. The years are open back to 2000 to the extent the NOLs being carried forward were generated then. The Company applies the provisions of ASC 740 related to accounting for uncertain tax positions and concluded there were no such positions associated with the Company requiring accrual of a liability. As of December 31, 2019, the Company has not accrued for any such positions. The Company is currently not under audit for federal or state tax purposes. The Company does not expect a significant change to occur within the next 12 months.

Retirement Benefits

Retirement Benefits	12 Months Ended
	Dec. 31, 2019
Compensation And Retirement Disclosure [Abstract]
Retirement Benefits	Note 16. Retirement Benefits The Company has a 401(k) retirement plan (the “Plan”) available for participation by all regular full-time employees who have completed three months of service with the Company. The Company established the Plan in 2008. The Plan provides for a discretionary matching contribution equal to 50% of the amount of the employee’s salary deduction, not to exceed 3% of the salary per employee. Highly compensated employees are excluded from receiving any discretionary matching contribution. Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment. The Company has the option to make discretionary matching contributions. The Company did not make discretionary matching contributions during the years ended December 31, 2019 and 2018.

Segment Reporting

Segment Reporting	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Segment and Geographic Information	Note 17. Segment and Geographic Information Management has determined that it has one business activity and operates in one segment as it only reports financial information on an aggregate and consolidated basis to its Chief Executive Officer, who is the Company’s chief operating decision maker. Revenues based on the location of the customers, are as follows (in thousands): Year Ended December 31, 2019 2018 United States $ 722 $ 1,168 India 7 90 Africa 182 115 Canada 258 91 Total $ 1,169 $ 1,464

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Net Loss per Share	Note 18. Net Loss per Share Basic net loss per share is calculated by dividing net loss attributable to common stockholders by the weighted­average number of common shares outstanding during the period and excludes any dilutive effects of stock­based awards and warrants. Diluted net loss per share attributable to common stockholders is computed giving effect to all potentially dilutive common shares, including common stock issuable upon exercise of stock options and warrants. As the Company had net losses for the years ended December 31, 2019 and 2018, all potentially dilutive common shares were determined to be anti­dilutive. Securities that were not included in the diluted per share calculations because they would be anti­dilutive were as follows (in shares): Year Ended December 31, 2019 2018 Options to purchase common stock 661,701 530,044 Warrants to purchase common stock 4,170,651 2,822,903 Total 4,832,352 3,352,947

Related Party Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Note 19. Related Party Transactions The Company’s related parties include Moral Compass Corporation (“MCC”) and the John Sperling Foundation (“JSF”). The rights to the intellectual property owned by Blue Horse Labs, Inc. (“BHL”) were assigned to its sole shareholder, the John Sperling Revocable Trust (“JSRT”) due to BHL’s dissolution and then subsequently to the JSF. The JSF is deemed a related party of the Company because MCC, the Company’s largest stockholder, and the JSF share common officers and directors. Transactions with related parties are reflected in the consolidated financial statements under amounts due to related parties. Outlined below are details of agreements between the Company and its related parties: JSF receives a single digit royalty from the Company when revenue has been collected on product sales or for license payments from third parties that involve certain intellectual property developed under research funding originally from BHL. Royalty fees due to JSF were $40,000 and $29,000 as of December 31, 2019 and December 31, 2018, respectively, and are included in the Consolidated Balance Sheets as amounts due to related parties.

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 20. Subsequent Events The Company has reviewed and evaluated subsequent events through March 25, 2020, the date the consolidated financial statements were available to be issued. Leases In January 2020, the Company entered into a lease amendment for additional office space in Davis, CA, and extended the term through April 2025, with one option to renew for an additional five-year term. The lease is expected to commence in the second quarter of 2020.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2019
Organization	Organization Arcadia Biosciences, Inc. (the "Company"), was incorporated in the state of Arizona in 2002 and maintains its headquarters in Davis, California, with additional facilities in Phoenix, Arizona, American Falls, Idaho, and Molokai, Hawaii. The Company was reincorporated in Delaware in March 2015. We are a leader in science-based approaches to developing high value crop productivity traits primarily in hemp, wheat, and soybean, designed to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients, health and wellness products, and their viability for industrial applications. We use state of the art gene-editing technology and advanced breeding techniques to develop these proprietary innovations which we are beginning to monetize through a number of methods including seed and grain sales, product extract sales, trait licensing and royalty agreements. In February 2012, the Company formed Verdeca LLC (“Verdeca,” see Note 7), which is jointly owned by us with Bioceres, Inc. (“Bioceres”), a U.S. wholly owned subsidiary of Bioceres, S.A., an Argentine corporation. Bioceres, S.A. is an agricultural investment and development cooperative. Verdeca , On August 9, 2019, the Company entered into a joint venture agreement with Legacy Ventures Hawaii, LLC (“Legacy,” see Note 6) to grow, extract, and sell hemp products. The new partnership, Archipelago Ventures Hawaii, LLC (“Archipelago”), combines the Company’s extensive genetic expertise and resources with Legacy’s experience in hemp extraction and sales.
Reverse Stock Split	Reverse Stock Split In January 2018, the Company’s board of directors approved a reverse split of 1:20 on the Company’s issued and outstanding common stock which became effective on January 23, 2018. All issued and outstanding common stock, options to purchase common stock and per share amounts contained in the consolidated financial statements have been retroactively adjusted to reflect the reverse stock split for all periods presented. The reverse stock split did not change the total number of authorized shares of common stock which remained at one hundred and fifty million shares
Liquidity, Capital Resources, and Going Concern	Liquidity, Capital Resources, and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities during the normal course of business. Since inception, the Company has financed its operations primarily through equity and debt financings. As of December 31, 2019, the Company had an accumulated deficit of $207.2 million, cash and cash equivalents of $8.4 million, and short-term investments of $16.9 million. For the years ended December 31, 2019 and 2018, the Company had net losses of $28.9 million and $13.5 million, respectively, and net cash used in operations of $17.2 million and $13.6 million, respectively. The Company believes that its existing cash, cash equivalents and investments will be insufficient to meet its anticipated cash requirements for at least through March 2021, and thus raises substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company may seek to raise additional At this time, there is significant uncertainty relating to the trajectory of the novel coronavirus outbreak and impact of related responses. The continued spread of the outbreak could materially harm our business, results of operations, and financial condition. Due to this uncertainty and plans outside of management’s control, we may not be able to achieve and implement such plans within one year after the date that the financial statements are issued to address the substantial doubt that exists.
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The consolidated financial statements include the accounts of the Company, Verdeca LLC and Archipelago. All intercompany balances and transactions have been eliminated in consolidation. The Company prepares its consolidated financial statements in conformity with accounting principles generally accepted in the United States of America, or U.S. GAAP (“GAAP”), and with the rules of the Securities and Exchange Commission. The Company uses a qualitative approach in assessing the consolidation requirement for variable interest entities ("VIEs"). This approach focuses on determining whether the Company has the power to direct the activities of the VIE that most significantly affect the VIE’s economic performance and whether the Company has the obligation to absorb losses, or the right to receive benefits, that could potentially be significant to the VIE. For all periods presented, the Company has determined that it is the primary beneficiary of Verdeca, which is a VIE. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. The Company evaluates its relationships with its VIEs upon the occurrence of certain significant events that affect the design, structure or other factors pertinent to the primary beneficiary determination. Verdeca LLC has no operations, assets or liabilities as of and for the years ended December 31, 2019 and 2018. For all periods presented, the Company has determined that it is the primary beneficiary of Archipelago, a joint venture, as it has a controlling interest in Archipelago. Accordingly, the Company consolidates the entity in the condensed consolidated financial statements after eliminating intercompany transactions. For consolidated joint ventures, the non-controlling partner’s share of the assets, liabilities and operations of the joint venture is included in non-controlling interests as equity of the Company. The non-controlling partner’s interest is generally computed as the joint venture partner’s ownership percentage of Archipelago. Net loss attributable to non-controlling interest of $68,000 is recorded as an adjustment to net loss to arrive at net loss attributable to common stockholders for the year ended December 31, 2019. The non-controlling partner’s equity interests are presented as non-controlling interests on the Consolidated Balance Sheets as of December 31, 2019.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions in the Company’s consolidated financial statements and notes thereto. Significant estimates and assumptions made by management included the determination of the provision for income taxes, stock-based compensation, fair value of certain equity instruments, and net realizable value of inventory. Management bases its estimates on historical experience and on various other market-specific and relevant assumptions that management believes to be reasonable under the circumstances. Actual results could differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers any liquid investments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks. The Company limits cash investments to financial institutions with high credit standings; therefore, management believes that there is no significant exposure to any credit risk in the Company’s cash and cash equivalents. However, as of December 31, 2019 and 2018, a substantial portion of the Company’s cash in depository accounts is in excess of the federal deposit insurance limits.
Investments in Debt Securities	Investments in Debt Securities Investments in debt securities are carried at fair value and classified as available-for-sale. Realized gains and losses on available-for-sale securities are included in other income — net in the Consolidated Statements of Operations and Comprehensive Loss. Unrealized gains and losses, net of deferred taxes, on available-for-sale securities are included in the Consolidated Balance Sheets as a component of accumulated other comprehensive income. Securities classified as available-for-sale are reported as cash and cash equivalent, short-term investments or long-term investments in the Consolidated Balance Sheets based on the nature of the investments and maturity period. Short-term investments have maturities of less than a year and long-term investments have maturities of a year and greater from the balance sheet date. The Company’s debt securities are primarily comprised of U.S. government securities, treasury bills, commercial paper, corporate securities, and money markets. These available-for-sale investments are held in the custody of a major financial institution.
Other-than-Temporary Impairments on Investment	Other-than-Temporary Impairments on Investment The Company regularly reviews each of its investments for impairment by determining if the investment has sustained an other-than-temporary decline in its value, in which case the investment is written down to its fair value by a charge to earnings. Factors that are considered by the Company in determining whether an other-than-temporary decline in value has occurred include (i) the market value of the investment in relation to its cost basis, (ii) the financial condition of the investment, and (iii) the Company’s intent and ability to retain the investment for a sufficient period of time to allow for recovery of the market value of the investment. As of December 31, 2019 and 2018, there was no impairment of the Company’s investments.
Accounts Receivable	Accounts Receivable Accounts receivable represents amounts owed to the Company from product sales, licenses and contract research and government grants. The carrying value of the Company’s receivables represents estimated net realizable values. The Company generally does not require collateral and estimates any required allowance for doubtful accounts based on historical collection trends, the age of outstanding receivables, and existing economic conditions. If events or changes in circumstances indicate that specific receivable balances may be impaired, further consideration is given to the collectability of those balances and the allowance is recorded accordingly. Past-due receivable balances are written off when the Company’s internal collection efforts have been unsuccessful in collecting the amounts due. The Company had no amounts reserved for doubtful accounts at December 31, 2019 and 2018 as the Company expected full collections of all accounts receivable balances as of each of these dates.
Inventory	Inventory GoodWheat: Propriety wheat plants are grown, producing seed with a variety of improved nutritional qualities, including high levels of amylose, improved shelf-life, and reduced gluten. This seed is used for subsequent plantings or processed, and sold as GoodWheat seeds, grain, and flour, which we refer to collectively as our GoodWheat products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops, costs to process and store harvested seed and grain, and costs to mill the grain into flour. SONOVA® Gamma Linolenic Acid (“GLA”) Safflower Oil: Proprietary safflower plants are grown, producing seed with a high-GLA content. This seed is used for subsequent plantings or processed, and sold as GLA oil, including SONOVA 400 GLA safflower oils and SONOVA Ultra GLA safflower oil, which we refer to collectively as our SONOVA products. Amounts inventoried consist primarily of fees paid to contracted cooperators to grow the crops and costs to process and store harvested seed. Hemp seeds are procured for the purpose of planting, harvesting, and extracting CBD oil to eventually be sold. Amounts inventories consist primarily of fees paid to suppliers to obtain the seeds. Inventory costs are tracked on a lot-identified basis and are included as cost of product revenues when sold. Inventories are stated at the lower of cost or net realizable value. The Company makes adjustments to inventory when conditions indicate that the net realizable value may be less than cost due to physical deterioration, obsolescence, changes in price levels, or other factors. Additional adjustments to inventory are made for excess and slow-moving inventory on hand that is not expected to be sold within a reasonable timeframe to reduce the carrying amount to its estimated net realizable value. The write downs to inventory are based upon estimates about future demand from the Company’s customers and distributors and market conditions. The Company recorded $304,000 and $310,000 of inventory write-downs for the years ended December 31, 2019 and 2018, respectively. The inventories—current line item on the balance sheet consists of the cost of GoodWheat seed, grain, and flour, GLA oil, and hemp seed inventory forecasted to be sold or used in production in the next 12 months, as of the balance sheet date. The inventories—noncurrent line item consists of GLA oil and seed inventory expected to be used in production or sold beyond the next 12 months, as of the balance sheet date. Raw materials inventories consist primarily of the cost of hemp seeds and GLA seed production costs incurred by our contracted cooperators. Goods in process inventories consist of costs to process hemp seed and GoodWheat seed and grain. Finished goods inventories consist of GoodWheat products and GLA oil that are available for sale. Inventories, net consist of the following (in thousands): As of December 31, 2019 2018 Raw Materials $ 67 $ 41 Goods in process 188 — Finished Goods 1,903 886 Inventories, net $ 2,158 $ 927
Property and Equipment	Property and Equipment Property and equipment acquisitions are recorded at cost. Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2-20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2-10 * * Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company evaluates if events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets and identifiable intangible assets may warrant revision or that the remaining balance of these assets may not be recoverable. In evaluating for recoverability, the Company estimates the future undiscounted cash flows expected to result from the use of the assets and their eventual disposition. In the event that the balance of any asset exceeds the future undiscounted cash flow estimate, impairment is recognized based on the excess of the carrying amounts of the asset above its estimated fair value. As of December 31, 2019 and 2018, there was no impairment of the Company’s long-lived assets.
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value accounting is applied for all financial assets and liabilities and non-financial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Assets and liabilities recorded at fair value in the consolidated financial statements are categorized based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows: • Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company can access at the measurement date. • Level 2 inputs are observable inputs other than quoted prices in active markets for identical assets and liabilities, quoted prices for identical or similar assets or liabilities in inactive markets, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 inputs are unobservable inputs for the asset or liability. The carrying values of the Company’s financial instruments, including cash equivalents, accounts receivable, accounts payable, and notes payable approximated their fair values due to the short period of time to maturity or repayment.
Concentration of Risk	Concentration of Risk Cash and cash equivalents are maintained with several financial institutions. Deposits held with banks may exceed the amount of insurance provided on such deposits. Generally, these deposits may be redeemed upon demand and are maintained with financial institutions with reputable credit and therefore bear minimal credit risk. The Company seeks to mitigate its credit risks by spreading such risks across multiple counterparties and monitoring the risk profiles of these counterparties.
Customer Concentration	Customer Concentration Significant customers are those that represent greater than 10% of the Company’s total revenues or gross accounts receivable balance at each respective balance sheet date. The Company had three customers that represented 47%, 17%, and 15% of accounts receivable, and three customers that represented 44%, 34%, and 13% of accounts receivable, as of December 31, 2019 and 2018, respectively. The Company had two customers that represented 40% and 15% of total revenues, and four customers that represented 19%, 16%, 13%, and 11% of total revenues, for the years ended December 31, 2019 and 2018, respectively.
Stock-Based Compensation	Stock-Based Compensation The Company recognizes compensation expense related to its employee stock purchase plan and the cost of stock-based compensation awards on a straight-line basis over the requisite service period, net of estimated forfeitures. Judgment is required in estimating the amount of stock-based awards that will be forfeited prior to vesting. Compensation expense could be revised in subsequent periods if actual forfeitures differ from those estimates. The Company has selected the Black-Scholes option-pricing model and various inputs to estimate the fair value of its stock-based awards. See Note 12 for additional information. Amounts recognized in the Consolidated Statements of Operations and Comprehensive Loss were as follows (in thousands): Year Ended December 31, 2019 2018 (in thousands) Research and development $ 321 $ 379 Selling, general and administrative 1,966 1,171 Total stock-based compensation $ 2,287 $ 1,550
Income Taxes	Income Taxes The Company uses the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on the differences between the financial reporting and the tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.
Net Loss per Share	Net Loss per Share Basic net loss per share, which excludes dilution, is computed by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock, such as stock options, convertible promissory notes, convertible preferred stock, redeemable convertible preferred stock and warrants, result in the issuance of common stock which share in the losses of the Company. Certain potential shares of common stock have been excluded from the computation of diluted net loss per share as their effect would be anti-dilutive. Such potentially dilutive shares are excluded when the effect would be to reduce the loss per share. Due to net losses, there is no impact on earnings per share calculation in applying the two-class method since the participating securities have no legal requirement to share in any losses.
Revenue Recognition	Revenue Recognition We derive our revenues from product revenues, licensing agreements, royalties, contract research agreements, and government grants.
Unearned Revenue	Unearned Revenue The Company defers revenue to the extent that cash received in conjunction with a license agreement, contract or grant exceeds the revenue recognized in accordance with Company policies. During the year ended December 31, 2019, we recognized revenue of $96,000 that was included in unearned revenue on the consolidated balance sheet as of December 31, 2018.
Cost of Product Revenues	Cost of Product Revenues Cost of product revenues relates to the sale of our SONOVA and GoodWheat products and consists of in-licensing and royalty fees, any adjustments or write-downs to inventory, as well as the cost of raw materials, including inventory and third-party services costs related to procuring, processing, formulating, packaging, and shipping our products.
Research and Development Expenses	Research and Development Expenses Research and development expenses consist of costs incurred in the discovery, development, and testing of our products and products in development incorporating our traits. These expenses consist primarily of employee salaries and benefits, fees paid to subcontracted research providers, fees associated with in-licensing technology, land leased for field trials, chemicals and supplies, and other external expenses. These costs are expensed as incurred. Additionally, as disclosed in Note 13, the Company is required from time to time to make certain milestone payments in connection with the development of technologies in-licensed from third parties. These milestone payments are expensed at the time the milestone is achieved and deemed payable.
Change in Fair Value of Contingent Consideration	C hange in Fair Value of Contingent Consideration Change in the fair value of contingent consideration is comprised of the gain associated with the reduction of our contingent liability. See Note 13.
Change in the Estimated Fair Value of Common Stock Warrant Liabilities and Common Stock Adjustment Feature Liability	C hange in the Estimated Fair Value of Common Stock Warrant Liabilities and Common Stock Adjustment Feature Liability Change in the estimated fair value of common stock warrant liabilities and common stock adjustment feature liability is comprised of the fair value remeasurement of the liabilities associated with the March 2018 Private Placement and the June 2018, June 2019, and September 2019 Offerings. See Note 11.
Product Revenues
Revenue Recognition	Product Revenues Our product revenues to date have consisted primarily of sales of our SONOVA products, with initial GoodWheat seed sale revenues recognized in the fourth quarter of 2019. We recognize revenue from product sales when control of the product is transferred to third-party distributors and manufacturers, collectively “our customers,” which generally occurs upon shipment. Our revenues fluctuate depending on the timing of shipments of product to our customers.
License Revenues
Revenue Recognition	License Revenues Our license revenues to date consist of up-front, nonrefundable license fees, annual license fees, and subsequent milestone payments that we receive under our research and license agreements. We recognize revenue generated from up-front, nonrefundable license fees upon execution of the agreement. We recognize annual license fees when it is probable that a material reversal will not occur. Milestone fees are variable consideration that is initially constrained and recognized only when it is probable that such amounts would not be reversed. The Company assesses when achievement of milestones is probable to determine the timing of revenue recognition for milestone fees
Contract Research Revenues
Revenue Recognition	Contract Research Revenues Contract research and government grant revenues consist of amounts earned from performing contracted research primarily related to breeding programs or the genetic engineering of plants for third parties. Contract research revenue is accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g. costs incurred to date relative to the total estimated costs at completion).
Government Grant Revenues
Revenue Recognition	Government Grant Revenues The Company receives payments from government entities in the form of government grants. Government grant revenue is accounted for as a single performance obligation for which revenues are recognized over time using the input method (e.g. costs incurred to date relative to the total estimated costs at completion). The Company’s obligation with respect to these agreements is to perform the research on a best-efforts basis.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2019
Accounting Policies [Abstract]
Summary of Inventories, Net	Inventories, net consist of the following (in thousands): As of December 31, 2019 2018 Raw Materials $ 67 $ 41 Goods in process 188 — Finished Goods 1,903 886 Inventories, net $ 2,158 $ 927
Summary of Average Estimated Useful Lives of Assets	Provisions for depreciation are calculated using the straight-line method over the following average estimated useful lives of the assets: Years Laboratory equipment 5 Software and computer equipment 3 Machinery and equipment 2-20 Furniture and fixtures 7 Vehicles 5 Leasehold improvements 2-10 * * Leasehold improvements are depreciated over the shorter of the estimated life of the asset or the remaining life of the lease.
Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net	Amounts recognized in the Consolidated Statements of Operations and Comprehensive Loss were as follows (in thousands): Year Ended December 31, 2019 2018 (in thousands) Research and development $ 321 $ 379 Selling, general and administrative 1,966 1,171 Total stock-based compensation $ 2,287 $ 1,550

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	12 Months Ended
	Dec. 31, 2019
Property Plant And Equipment [Abstract]
Summary of Property and Equipment, Net	Property and equipment, net consisted of the following (in thousands): As of December 31, 2019 2018 Laboratory equipment $ 2,443 $ 2,348 Software and computer equipment 502 477 Machinery and equipment 989 — Furniture and fixtures 90 85 Vehicles 395 204 Leasehold improvements 2,023 2,082 Property and equipment, gross 6,442 5,196 Less accumulated depreciation and amortization (4,643 ) (4,801 ) Property and equipment, net $ 1,799 $ 395

Investments and Fair Value Me_2

Investments and Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2019
Investments And Fair Value Measurements [Abstract]
Summary of Amortized Cost and Fair Value of the Available-For-Sale Investment Securities Portfolio	The following tables summarize the amortized cost and fair value of the available-for-sale investment securities portfolio at December 31, 2019 and December 31, 2018, and the corresponding amounts of unrealized gains and losses recognized in accumulated other comprehensive income: (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2019 Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper 900 — — 900 Short-term investments: Corporate securities 3,300 — — 3,300 Treasury bills 1,495 1 — 1,496 Commercial paper 12,119 — — 12,119 Total Assets at Fair Value $ 24,678 $ 1 $ — $ 24,679 (Dollars in thousands) Amortized Cost Unrealized Gains Unrealized Losses Estimated Fair Value December 31, 2018 Cash equivalents: Money market funds $ 9,902 $ — $ — $ 9,902 Commercial paper 1,345 — — 1,345 Short-term investments: Corporate securities 656 — — 656 Treasury bills 1,195 — — 1,195 Commercial paper 6,776 — — 6,776 U.S. government securities 1,198 — — 1,198 Total Assets at Fair Value $ 21,072 $ — $ — $ 21,072
Summary of Fair Value of Available-for-Sale Investments	The fair value of the available-for-sale investments at December 31, 2019 were as follows: Fair Value Measurements at December 31, 2019 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 6,864 $ — $ — $ 6,864 Commercial paper — 900 — 900 Short-term investments: Corporate securities — 3,300 — 3,300 Treasury bills 1,496 — — 1,496 Commercial paper — 12,119 — 12,119 Total Assets at Fair Value $ 8,360 $ 16,319 $ — $ 24,679 The fair value of the available-for-sale investments at December 31, 2018 were as follows: Fair Value Measurements at December 31, 2018 (Dollars in thousands) Level 1 Level 2 Level 3 Total Assets at Fair Value Cash equivalents: Money market funds $ 9,902 $ — $ — $ 9,902 Commercial paper — 1,345 — 1,345 Short-term investments: Corporate securities — 656 — 656 Treasury bills 1,195 — — 1,195 Commercial paper — 6,776 — 6,776 U.S. government securities 1,198 — — 1,198 Total Assets at Fair Value $ 12,295 $ 8,777 $ — $ 21,072
Summary of Warrant Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model	T he warrant liabilities were measured and recorded on a recurring basis Assumptions: Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Common Stock Warrant Liability - June 2019 Offering Common Stock Warrant Liability - September 2019 Offering Stock price $ 5.48 $ 5.48 $ 5.48 $ 5.48 Expected term (years) 3.22 3.96 4.96 5.20 Expected volatility 125% 123% 120% 120% Risk-free interest rate 1.63% 1.65% 1.69% 1.70% Expected dividend yield — — — — The warrant liabilities were measured and recorded on a recurring basis using the Black-Scholes Model with the following assumptions as of December 31, 2018: Assumptions: Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Stock price $ 3.17 $ 3.17 Expected term (years) 4.22 4.96 Expected volatility 110% 105% Risk-free interest rate 2.49% 2.50% Expected dividend yield — —
Summary of Changes in Fair Value and Other Adjustments of Liabilities	The following table sets forth the establishment of the Company’s Level 3 liabilities, as well as a summary of the changes in the fair value and other adjustments (in thousands): (Level 3) (Dollars in thousands) Common Stock Warrant Liability - March 2018 Purchase Agreement Common Stock Adjustment Feature Liability - March 2018 Purchase Agreement Common Stock Warrant Liability - June 2018 Offering Common Stock Warrant Liability - June 2019 Offering Common Stock Warrant Liability - September 2019 Offering Contingent Liability Total Balance as of December 31, 2017 $ — $ — $ — $ — $ — $ 3,000 $ 3,000 Common stock and warrants issued in conjunction with March 2018 Offering 10,200 3,800 — — — — $ 14,000 Common stock and warrants issued in conjunction with June 2018 Offering — — 9,022 — — — $ 9,022 Change in fair value and other adjustments (7,846 ) 4,578 (6,293 ) — — — $ (9,561 ) Reclassification of common stock adjustment feature liability balance to equity — (8,378 ) — — — — $ (8,378 ) Balance as of December 31, 2018 2,354 — 2,729 — — 3,000 $ 8,083 Common stock and warrants issued in conjunction with June 2019 Offering — — — 4,198 — — $ 4,198 Common stock and warrants issued in conjunction with September 2019 Offering — — — — 3,428 — $ 3,428 Change in fair value and other adjustments 2,225 — 2,715 4,811 (508 ) (1,000 ) $ 8,243 Exercise of warrants — — — (7,016 ) — — $ (7,016 ) Balance as of December 31, 2019 $ 4,579 $ — $ 5,444 $ 1,993 $ 2,920 $ 2,000 $ 16,936

Accounts Payable and Accrued _2

Accounts Payable and Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2019
Payables And Accruals [Abstract]
Summary of Accounts Payable and Accrued Expenses	Accounts payable and accrued expenses consisted of the following (in thousands): As of December 31, 2019 2018 Accounts payable - trade $ 492 $ 285 Payroll and benefits 1,290 1,096 Inventory 1,143 — Research and development 629 433 Royalty fees due to unrelated parties 226 187 Consulting 397 92 Rent and utilities 23 91 Audit and tax fees 113 23 Legal 138 285 Other 234 153 Total accounts payable and accrued expenses $ 4,685 $ 2,645

Notes Payable (Tables)

Notes Payable (Tables)	12 Months Ended
	Dec. 31, 2019
Debt Disclosure [Abstract]
Summary of Maturities of Notes Payable	Maturities of notes payable as of December 31, 2019 are as follows (in thousands): Years Ending December 31, Amounts 2020 $ 24 2021 27 2022 29 2023 31 2024 20 Total notes payable $ 131 Less: current portion 24 Notes payable - noncurrent $ 107

Stock-Based Compensation and _2

Stock-Based Compensation and Warrants (Tables)	12 Months Ended
	Dec. 31, 2019
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Activity Under Stock Incentive Plans	The following is a summary of stock option information and weighted average exercise prices under the Company’s stock incentive plans (in thousands, except share data and price per share): Shares Subject to Outstanding Options Weighted- Average Exercise Price Per Share Aggregate Intrinsic Value Outstanding — Balance at December 31, 2017 288,129 $ 63.62 $ — Options granted 302,077 6.65 Options exercised (44,354 ) 21.73 Options forfeited (4,006 ) 14.21 Options expired (11,802 ) 43.73 Outstanding — Balance at December 31, 2018 530,044 35.53 $ — Options granted 208,571 5.13 Options exercised (546 ) 4.63 Options forfeited (30,132 ) 33.95 Options expired (46,236 ) 98.69 Outstanding — Balance at December 31, 2019 661,701 21.60 $ 305 Vested and expected to vest — December 31, 2019 654,170 21.74 $ 301 Exercisable —December 31, 2019 410,270 $ 29.24 $ 192
Weighted-Average Fair Value Assumption of Stock Option Awards	The Year Ended December 31, Assumptions 2019 2018 Expected term (years) 7.04 5.99 Expected volatility 99% 99% Risk-free interest rate 2.01% 2.95% Expected dividend yield — —

Commitment and Contingencies (T

Commitment and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2019
Commitments And Contingencies Disclosure [Abstract]
Schedule of Minimum Funding Requirements Under Non-Cancelable Agreement	The following table sets forth our minimum funding requirements under this agreement as of December 31, 2019 (in thousands): Years Ending December 31, Amounts 2020 $ 500 2021 750 2022 — 2023 — 2024 — Thereafter — Total $ 1,250

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2019
Lessee Disclosure [Abstract]
Schedule of Leases	Leases consisted of the following (in thousands): Leases Classification December 31, 2019 Assets Operating lease assets Right of use asset $ 1,963 Total leased assets $ 1,963 Liabilities Current - Operating Operating lease liability - current $ 611 Noncurrent - Operating Operating lease liability - noncurrent 1,497 Total leased liabilities $ 2,108 Lease Cost Classification For the Year Ended December 31, 2019 Operating lease cost SG&A and R&D Expenses $ 708 Short term lease cost (1) R&D Expenses 205 Sublease income (2) SG&A and R&D Expenses (55 ) Net lease cost $ 858 (1) Short term lease cost consists of field trial lease agreements with a lease term of 12 months or less. (2) Sublease income is recorded as a credit to lease expense. Lease Term and Discount Rate December 31, 2019 Weighted-average remaining lease term (years) 2.6 Weighted-average discount rate 7 %
Schedule of Maturities of Operating Lease Liabilities	The maturities of our operating lease liabilities as of December 31, 2019 are as follows (in thousands): Years Ending December 31, Amounts 2020 $ 735 2021 681 2022 575 2023 372 Total operating lease payments $ 2,363 Less: imputed interest $ 255 Total current and noncurrent operating lease liabilities $ 2,108

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Components of Loss Before Income Taxes	The components of loss before income taxes are as follows (in thousands): Year Ended December 31, 2019 2018 Domestic $ (28,871 ) $ (13,470 ) Foreign — — Loss before income taxes $ (28,871 ) $ (13,470 )
Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes	The total income tax expense for the years ended December 31, 2019 and 2018 was $2,000 and $10,000, respectively, and is comprised of current state taxes and foreign taxes withheld by governmental agencies outside of the United States, as follows (in thousands): Year Ended December 31, 2019 2018 Current: Federal $ — $ — State 2 1 Foreign — 9 Total current tax expense 2 10 Deferred: Federal — — State — — Foreign — — Total deferred tax asset — — Total tax expense $ 2 $ 10
Reconciliation of the Statutory Federal Income Tax Rate	The following is a reconciliation of the statutory federal income tax rate to the Company’s effective tax rate is as follows: Year Ended December 31, 2019 2018 Expected income tax provision at the federal statutory rate 21.0 % 21.0 % State taxes, net of federal benefit 5.3 % 8.5 % Change in valuation allowance (26.4 )% (27.3 )% Transaction costs — (2.9 )% Related offering costs (0.5 )% (1.1 )% Excess windfall benefit — 1.4 % Withholding taxes — (0.1 )% Other 0.6 % 0.4 % Income tax provision — (0.1 )%
Deferred Tax Assets and Liabilities	Significant components of the Company’s deferred tax assets and liabilities are as follows (in thousands) As of December 31, 2019 2018 Deferred tax assets: Net operating loss carryforwards $ 13,267 $ 42,097 Unearned revenue 11 26 Stock-based compensation 3,384 2,855 Accrued payroll and benefits 224 255 Research and development credits — 171 Fixed asset basis difference 90 114 Inventory reserve 568 508 Operating lease liability 565 — Common stock warrant assets 988 — Charitable contributions 2 3 Total deferred tax assets 19,099 46,029 Deferred tax liabilities: Right of use asset (526 ) — Common stock warrant liabilities — (1,529 ) Total deferred tax liabilities (526 ) (1,529 ) Less valuation allowance (18,573 ) (44,500 ) Net deferred tax assets $ — $ —

Segment Reporting (Tables)

Segment Reporting (Tables)	12 Months Ended
	Dec. 31, 2019
Segment Reporting [Abstract]
Summary of Revenues Based on Location of Customers	Revenues based on the location of the customers, are as follows (in thousands): Year Ended December 31, 2019 2018 United States $ 722 $ 1,168 India 7 90 Africa 182 115 Canada 258 91 Total $ 1,169 $ 1,464

Net Loss per Share (Tables)

Net Loss per Share (Tables)	12 Months Ended
	Dec. 31, 2019
Earnings Per Share [Abstract]
Schedule of Securities Not Included in Diluted per Share Calculations	Securities that were not included in the diluted per share calculations because they would be anti­dilutive were as follows (in shares): Year Ended December 31, 2019 2018 Options to purchase common stock 661,701 530,044 Warrants to purchase common stock 4,170,651 2,822,903 Total 4,832,352 3,352,947

Description of Business - Addit

Description of Business - Additional Information (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)shares	Dec. 31, 2018USD ($)shares
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Place of incorporation	Arizona
Year of incorporation	2002
Place of reincorporation	Delaware
Date of reincorporation	2015-03
Reverse split of issued and outstanding common stock	1:20
Stock split conversion ratio	0.05
Common stock, authorized | shares	150,000,000	150,000,000
Accumulated deficit	$ (207,171)	$ (178,366)
Cash and cash equivalents	8,417	11,998
Short-term investments	16,915	9,825
Net losses	(28,873)	(13,480)
Net cash used in operations	$ (17,198)	$ (13,631)

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Line Items]
VIEs Operations	$ (19,381,000)	$ (16,870,000)
Net loss attributable to noncontrolling interest	68,000
Reserved for doubtful accounts	0	0
Inventory write-downs	304,000	310,000
Impairment of long-lived assets	0	$ 0
Revenue recognized	$ 96,000
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer One [Member]
Accounting Policies [Line Items]
Concentration risk percentage	47.00%	44.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Two [Member]
Accounting Policies [Line Items]
Concentration risk percentage	17.00%	34.00%
Customer Concentration Risk [Member] | Accounts Receivable [Member] | Customer Three [Member]
Accounting Policies [Line Items]
Concentration risk percentage	15.00%	13.00%
Customer Concentration Risk [Member] | Total Revenue [Member] | Customer One [Member]
Accounting Policies [Line Items]
Concentration risk percentage	40.00%	19.00%
Customer Concentration Risk [Member] | Total Revenue [Member] | Customer Two [Member]
Accounting Policies [Line Items]
Concentration risk percentage	15.00%	16.00%
Customer Concentration Risk [Member] | Total Revenue [Member] | Customer Three [Member]
Accounting Policies [Line Items]
Concentration risk percentage		13.00%
Customer Concentration Risk [Member] | Total Revenue [Member] | Customer Four [Member]
Accounting Policies [Line Items]
Concentration risk percentage		11.00%
Limagrain Cereal Seeds LLC [Member]
Accounting Policies [Line Items]
Impairment of equity method investments	$ 0	$ 0
Verdeca LLC [Member]
Accounting Policies [Line Items]
VIEs Operations	0	0
VIEs assets or liabilities	$ 0	$ 0

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Inventories, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw Materials	$ 67	$ 41
Goods in process	188
Finished Goods	1,903	886
Inventories, net	$ 2,158	$ 927

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Average Estimated Useful Lives of Assets (Detail)	12 Months Ended
	Dec. 31, 2019
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	3 years
Machinery and equipment [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Machinery and equipment [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	20 years
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	7 years
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	5 years
Leasehold improvements [Member] | Minimum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	2 years
Leasehold improvements [Member] | Maximum [Member]
Property Plant And Equipment [Line Items]
Property and equipment, estimated useful lives	10 years

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Amounts Recognized in Consolidated Statements of Operations and Comprehensive Loss Net (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 2,287	$ 1,550
Research and Development [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	321	379
Selling, General and Administrative [Member]
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Total stock-based compensation	$ 1,966	$ 1,171

Property and Equipment, Net - S

Property and Equipment, Net - Summary of Property and Equipment, Net (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 6,442	$ 5,196
Less accumulated depreciation and amortization	(4,643)	(4,801)
Property and equipment, net	1,799	395
Laboratory equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	2,443	2,348
Software and computer equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	502	477
Machinery and equipment [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	989
Furniture and fixtures [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	90	85
Vehicles [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	395	204
Leasehold improvements [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 2,023	$ 2,082

Property and Equipment, Net - A

Property and Equipment, Net - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Property Plant And Equipment [Line Items]
Depreciation expense	$ 194,000	$ 154,000
Property and equipment, gross	6,442,000	5,196,000
Construction in Progress [Member]
Property Plant And Equipment [Line Items]
Property and equipment, gross	$ 1,014,000	$ 10,000

Investments and Fair Value Me_3

Investments and Fair Value Measurements - Summary of Amortized Cost and Fair Value of the Available-For-Sale Investment Securities Portfolio (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 24,678	$ 21,072
Unrealized Gains	1	0
Unrealized Losses	0	0
Estimated Fair Value	24,679	21,072
Cash Equivalents [Member] | Money Market Funds [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	6,864	9,902
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	6,864	9,902
Cash Equivalents [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	900	1,345
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	900	1,345
Short-term Investments [Member] | Commercial Paper [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	12,119	6,776
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	12,119	6,776
Short-term Investments [Member] | Treasury Bills [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	1,495	1,195
Unrealized Gains	1	0
Unrealized Losses	0	0
Estimated Fair Value	1,496	1,195
Short-term Investments [Member] | Corporate Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	3,300	656
Unrealized Gains	0	0
Unrealized Losses	0	0
Estimated Fair Value	$ 3,300	656
Short-term Investments [Member] | U.S. Government Securities [Member]
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost		1,198
Unrealized Gains		0
Unrealized Losses		0
Estimated Fair Value		$ 1,198

Investments and Fair Value Me_4

Investments and Fair Value Measurements - Additional Information (Detail)	Dec. 31, 2019USD ($)
Investments Debt And Equity Securities [Abstract]
Investment in continuous unrealized loss position for more than twelve months	$ 0

Investments and Fair Value of F

Investments and Fair Value of Financial Instruments - Summary of Fair Value of Financial Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Assets at Fair Value
Total Assets at Fair Value	$ 24,679	$ 21,072
Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	6,864	9,902
Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	900	1,345
Short-term investments	12,119	6,776
Treasury Bills [Member]
Assets at Fair Value
Short-term investments	1,496	1,195
U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments		1,198
Level 1 [Member]
Assets at Fair Value
Total Assets at Fair Value	8,360	12,295
Level 1 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	6,864	9,902
Level 1 [Member] | Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	0	0
Short-term investments	0	0
Level 1 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	1,496	1,195
Level 1 [Member] | U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments		1,198
Level 2 [Member]
Assets at Fair Value
Total Assets at Fair Value	16,319	8,777
Level 2 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 2 [Member] | Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	900	1,345
Short-term investments	12,119	6,776
Level 2 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	0	0
Level 2 [Member] | U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments		0
Level 3 [Member]
Assets at Fair Value
Total Assets at Fair Value	0	0
Level 3 [Member] | Money Market Funds [Member]
Assets at Fair Value
Cash equivalents	0	0
Level 3 [Member] | Commercial Paper [Member]
Assets at Fair Value
Cash equivalents	0	0
Short-term investments	0	0
Level 3 [Member] | Treasury Bills [Member]
Assets at Fair Value
Short-term investments	0	0
Level 3 [Member] | U.S. Government Securities [Member]
Assets at Fair Value
Short-term investments		0
Corporate Securities [Member]
Assets at Fair Value
Short-term investments	3,300	656
Corporate Securities [Member] | Level 1 [Member]
Assets at Fair Value
Short-term investments	0	0
Corporate Securities [Member] | Level 2 [Member]
Assets at Fair Value
Short-term investments	3,300	656
Corporate Securities [Member] | Level 3 [Member]
Assets at Fair Value
Short-term investments	$ 0	$ 0

Investments and Fair Value of_2

Investments and Fair Value of Financial Instruments - Summary of Warrant Liabilities Measured and Recorded on Recurring Basis using Black-Scholes Model (Detail)	Dec. 31, 2019$ / shares	Dec. 31, 2018$ / shares
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 32.52
Common Stock Warrant Liability [Member] | Purchase Agreement [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	5.48	$ 3.17
Common Stock Warrant Liability [Member] | June 2018 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	5.48	$ 3.17
Common Stock Warrant Liability [Member] | June 2019 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	5.48
Common Stock Warrant Liability [Member] | September 2019 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Stock price	$ 5.48
Expected Term [Member] | Common Stock Warrant Liability [Member] | Purchase Agreement [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (years)	3 years 2 months 19 days	4 years 2 months 19 days
Expected Term [Member] | Common Stock Warrant Liability [Member] | June 2018 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (years)	3 years 11 months 15 days	4 years 11 months 15 days
Expected Term [Member] | Common Stock Warrant Liability [Member] | June 2019 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (years)	4 years 11 months 15 days
Expected Term [Member] | Common Stock Warrant Liability [Member] | September 2019 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Expected term (years)	5 years 2 months 12 days
Expected Volatility [Member] | Common Stock Warrant Liability [Member] | Purchase Agreement [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	125	110
Expected Volatility [Member] | Common Stock Warrant Liability [Member] | June 2018 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	123	105
Expected Volatility [Member] | Common Stock Warrant Liability [Member] | June 2019 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	120
Expected Volatility [Member] | Common Stock Warrant Liability [Member] | September 2019 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	120
Risk-Free Interest Rate [Member] | Common Stock Warrant Liability [Member] | Purchase Agreement [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.63	2.49
Risk-Free Interest Rate [Member] | Common Stock Warrant Liability [Member] | June 2018 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.65	2.50
Risk-Free Interest Rate [Member] | Common Stock Warrant Liability [Member] | June 2019 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.69
Risk-Free Interest Rate [Member] | Common Stock Warrant Liability [Member] | September 2019 Offering [Member] | Level 3 [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]
Warrants and rights outstanding, measurement input	1.70

Investments and Fair Value of_3

Investments and Fair Value of Financial Instruments - Summary of Changes in Fair Value of Liabilities (Detail) - Level 3 [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	$ 8,083	$ 3,000
Change in fair value and other adjustments	8,243	(9,561)
Reclassification of common stock adjustment feature liability balance to equity		(8,378)
Exercise of warrants	(7,016)
Ending Balance	16,936	8,083
Common Stock Warrant Liability [Member] | Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,354	0
Common stock and warrants issued		10,200
Change in fair value and other adjustments	2,225	(7,846)
Reclassification of common stock adjustment feature liability balance to equity		0
Exercise of warrants	0
Ending Balance	4,579	2,354
Common Stock Warrant Liability [Member] | June 2018 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	2,729	0
Common stock and warrants issued		9,022
Change in fair value and other adjustments	2,715	(6,293)
Reclassification of common stock adjustment feature liability balance to equity		0
Exercise of warrants	0
Ending Balance	5,444	2,729
Common Stock Warrant Liability [Member] | June 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0	0
Common stock and warrants issued	4,198
Change in fair value and other adjustments	4,811	0
Reclassification of common stock adjustment feature liability balance to equity		0
Exercise of warrants	(7,016)
Ending Balance	1,993	0
Common Stock Warrant Liability [Member] | September 2019 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0	0
Common stock and warrants issued	3,428
Change in fair value and other adjustments	(508)	0
Reclassification of common stock adjustment feature liability balance to equity		0
Exercise of warrants	0
Ending Balance	2,920	0
Common Stock Warrant Liability [Member] | March 2018 Offering [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Common stock and warrants issued		14,000
Common Stock Adjustment Feature Liability [Member] | Purchase Agreement [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	0	0
Common stock and warrants issued		3,800
Change in fair value and other adjustments	0	4,578
Reclassification of common stock adjustment feature liability balance to equity		(8,378)
Exercise of warrants	0
Ending Balance	0	0
Contingent Liability [Member]
Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]
Beginning Balance	3,000	3,000
Common stock and warrants issued	0	0
Change in fair value and other adjustments	(1,000)	0
Reclassification of common stock adjustment feature liability balance to equity		0
Exercise of warrants	0
Ending Balance	$ 2,000	$ 3,000

Consolidated Joint Venture - Ad

Consolidated Joint Venture - Additional Information (Detail)	Aug. 09, 2019Individual	Dec. 31, 2019USD ($)
Schedule Of Equity Method Investments [Line Items]
Net loss attributable to noncontrolling interest		$ 68,000
Arcadia Biosciences, Inc [Member] | Archipelago Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		50.75%
Capital contributions		$ 709,000
Legacy Ventures Hawaii, LLC [Member] | Archipelago Ventures Hawaii, LLC [Member]
Schedule Of Equity Method Investments [Line Items]
Number of individuals appointed | Individual	2
Joint venture interest percentage		49.25%
Capital contributions		$ 689,000

Variable Interest Entity - Addi

Variable Interest Entity - Additional Information (Detail)	1 Months Ended	12 Months Ended
	Feb. 29, 2012Owner	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)
Variable Interest Entity [Line Items]
Variable interest entity agreement, terms		Both the Company and Bioceres incur expenses in support of specific activities agreed, as defined by joint work plans, which apply fair market value to each partner’s activities. Unequal contributions of services are equalized by the partners through cash payments. Verdeca is not the primary obligor for these activities performed by the Company or Bioceres. An agreement executed in conjunction with the formation of Verdeca specified that if Bioceres determines it requires cash to fund its contributed services (subject to certain annual limits), Bioceres, S.A. may elect to sell shares of its common stock to the Company for an amount not exceeding $5.0
Funding period of cash required for contributed services		4 years
Direct expenses and allocated overhead amount		$ 559,000	$ 947,000
Maximum [Member]
Variable Interest Entity [Line Items]
Commitment to purchase stock		$ 5,000,000
Bioceres, S.A. [Member]
Variable Interest Entity [Line Items]
Number of shareholders owning agricultural investment and development cooperative | Owner	300

Accounts Payable and Accrued _3

Accounts Payable and Accrued Expenses - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Payables And Accruals [Abstract]
Accounts payable - trade	$ 492	$ 285
Payroll and benefits	1,290	1,096
Inventory	1,143	0
Research and development	629	433
Royalty fees due to unrelated parties	226	187
Consulting	397	92
Rent and utilities	23	91
Audit and tax fees	113	23
Legal	138	285
Other	234	153
Total accounts payable and accrued expenses	$ 4,685	$ 2,645

Collaborative Arrangements - Ad

Collaborative Arrangements - Additional Information (Detail)	1 Months Ended
	Aug. 31, 2017
Collaborative Arrangements [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Contractual agreement month and year	2017-08

Notes Payable - Additional Info

Notes Payable - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Debt Disclosure [Abstract]
Notes payable interest rate	8.00%
Notes payable term	5 years
Notes payable maturity year	2024
Notes payable		$ 0

Notes Payable - Summary of Matu

Notes Payable - Summary of Maturities of Notes Payable (Detail) - Notes Payable [Member] $ in Thousands	Dec. 31, 2019USD ($)
Debt Instrument [Line Items]
2020	$ 24
2021	27
2022	29
2023	31
2024	20
Total notes payable	131
Less: current portion	24
Notes payable - noncurrent	$ 107

Private Placement and Registe_2

Private Placement and Registered Direct Offerings - Additional Information (Detail)

Sep. 05, 2019USD ($)$ / sharesshares

Jun. 12, 2019USD ($)$ / sharesshares

Jun. 11, 2018USD ($)$ / sharesshares

May 08, 2018$ / sharesshares

Apr. 23, 2018$ / sharesshares

Mar. 22, 2018$ / sharesshares

Mar. 19, 2018

Sep. 30, 2019USD ($)shares

Aug. 31, 2019shares

Sep. 30, 2019USD ($)

Jun. 30, 2018USD ($)

Dec. 31, 2019USD ($)$ / sharesshares

Dec. 31, 2018USD ($)

Dec. 20, 2019shares

Aug. 27, 2019shares

Feb. 15, 2019shares

May 07, 2018USD ($)

Class Of Warrant Or Right [Line Items]

Warrants issued, exercise price | $ / shares

$ 9.18

Period of trading days taken for calculation of volume weighted average price

3 days

Percentage of volume weighted average price of common stock

80.00%

Percentage of volume weighted average price of warrant

110.00%

Proceeds from issuance of private placement

$ 10,000,000

Offering costs

$ 226,000

Stock price | $ / shares

$ 32.52

Common stock no par value | $ / shares

Initial loss recognized on liabilities

$ 4,000,000

Offering cost, expense

708,000

$ 2,555,000

Issuance of placement agent warrants

526,000

Proceeds from issuance initial public offering

50,000,000

Fair value of common stock warrants at inception

9,000,000

Cash proceeds

$ 5,269,000

Warrant outstanding | shares

4,170,651

Warrants [Member]

Class Of Warrant Or Right [Line Items]

Issuance of placement agent warrants

$ 526,000

Placement Agent [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

15,038

Warrants issued, exercise price | $ / shares

$ 41.5625

Offering costs

$ 1,800,000

Warrant, exercisable term

5 years

Offering cost, expense

$ 1,800,000

June 2018 Placement Agent Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

69,617

Warrants issued, exercise price | $ / shares

$ 12.568

Offering costs

$ 1,600,000

Aggregate agent fee paid

$ 980,000

Warrant, exercisable term

5 years

Offering cost, expense

721,000

Issuance of placement agent warrants

$ 427,000

Offering costs portion attributable to common stock

$ 912,000

June 2018 Placement Agent Warrants [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

69,617

March 2018 Placement Agent [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

15,038

June 2018 Private Placement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

1,392,345

June 2019 Placement Agent Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

74,479

Warrants issued, exercise price | $ / shares

$ 6.2938

Offering costs

$ 115,000

Aggregate agent fee paid

$ 525,000

Warrant, exercisable term

5 years

Offering cost, expense

377,000

Issuance of placement agent warrants

$ 198,000

Offering costs portion attributable to common stock

489,000

June 2019 Placement Agent Warrants [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

74,479

Offering costs

$ 900,000

September 2019 Placement Agent Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

65,942

Warrants issued, exercise price | $ / shares

$ 9.4781

Offering costs

$ 113,000

Aggregate agent fee paid

$ 700,000

Warrant, exercisable term

5 years

Offering cost, expense

$ 331,000

Issuance of placement agent warrants

326,000

Offering costs portion attributable to common stock

808,000

September 2019 Placement Agent Warrants [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

65,942

Offering costs

$ 1,100,000

June 2019 Private Placement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

1,489,575

September 2019 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

659,414

Measurement Input, Price Volatility [Member]

Class Of Warrant Or Right [Line Items]

Volatility rate

1

Measurement Input, Risk Free Interest Rate [Member]

Class Of Warrant Or Right [Line Items]

Volatility rate

0.0263

Black Scholes Merton Model [Member]

Class Of Warrant Or Right [Line Items]

Stock price | $ / shares

$ 8.20

Black Scholes Merton Model [Member] | Measurement Input, Price Volatility [Member]

Class Of Warrant Or Right [Line Items]

Volatility rate

1.08

Black Scholes Merton Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class Of Warrant Or Right [Line Items]

Volatility rate

0.0283

Common Stock Adjustment Feature Liability [Member] | Monte Carlo Simulation Model [Member]

Class Of Warrant Or Right [Line Items]

Fair value of liabilities

$ 3,800,000

March 2018 Warrant Liability [Member] | Monte Carlo Simulation Model [Member]

Class Of Warrant Or Right [Line Items]

Fair value of liabilities

10,200,000

June 2018 Warrant Liability [Member]

Class Of Warrant Or Right [Line Items]

Liabilities marked to market value

5,400,000

2,700,000

Additional income (loss) on liabilities

(2,700,000)

6,300,000

Proceeds from issuance of common stock

5,000,000

Proceeds from issuance of common stock and warrants gross

14,000,000

June 2019 Warrant Liability [Member]

Class Of Warrant Or Right [Line Items]

Liabilities marked to market value

2,000,000

Additional income (loss) on liabilities

$ (6,500,000)

1,700,000

Proceeds from issuance of common stock

3,300,000

Proceeds from issuance of common stock and warrants gross

7,500,000

Fair value of common stock warrants at inception

4,200,000

Investors exercised warrants | shares

1,053,745

1,053,745

Cash proceeds

5,300,000

Exercised warrants

7,000,000

Unexercised warrants

$ 2,900,000

Warrant outstanding | shares

435,830

June 2019 Warrant Liability [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Liabilities marked to market value

$ 9,900,000

$ 9,900,000

June 2019 Warrant Liability [Member] | Black Scholes Merton Model [Member]

Class Of Warrant Or Right [Line Items]

Stock price | $ / shares

$ 3.66

June 2019 Warrant Liability [Member] | Black Scholes Merton Model [Member] | Measurement Input, Price Volatility [Member]

Class Of Warrant Or Right [Line Items]

Volatility rate

1.08

June 2019 Warrant Liability [Member] | Black Scholes Merton Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class Of Warrant Or Right [Line Items]

Volatility rate

0.0188

September 2019 Warrant Liability [Member]

Class Of Warrant Or Right [Line Items]

Liabilities marked to market value

$ 2,900,000

Additional income (loss) on liabilities

500,000

Proceeds from issuance of common stock

6,600,000

Proceeds from issuance of common stock and warrants gross

10,000,000

Fair value of common stock warrants at inception

$ 3,400,000

September 2019 Warrant Liability [Member] | Black Scholes Merton Model [Member]

Class Of Warrant Or Right [Line Items]

Stock price | $ / shares

$ 6.34

September 2019 Warrant Liability [Member] | Black Scholes Merton Model [Member] | Measurement Input, Price Volatility [Member]

Class Of Warrant Or Right [Line Items]

Volatility rate

1.16

September 2019 Warrant Liability [Member] | Black Scholes Merton Model [Member] | Measurement Input, Risk Free Interest Rate [Member]

Class Of Warrant Or Right [Line Items]

Volatility rate

0.0160

Minimum [Member]

Class Of Warrant Or Right [Line Items]

Warrants issued, exercise price | $ / shares

$ 8.322

Purchase price of common stock | $ / shares

$ 8.322

June 2018 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Offering costs

$ 1,200,000

Proceeds from issuance of common stock and warrants gross

14,000,000

Proceeds from issuance of common stock and warrants net

12,800,000

Securities Purchase Agreement [Member] | June 2019 Offering [Member]

Class Of Warrant Or Right [Line Items]

Offering costs

663,000

Proceeds from issuance of common stock and warrants gross

7,500,000

Proceeds from issuance of common stock and warrants net

6,800,000

Securities Purchase Agreement [Member] | September 2019 Offering [Member]

Class Of Warrant Or Right [Line Items]

Offering costs

799,000

Proceeds from issuance of common stock and warrants gross

10,000,000

Proceeds from issuance of common stock and warrants net

9,200,000

March 2018 Private Placement [Member]

Class Of Warrant Or Right [Line Items]

Proceeds from issuance of private placement

8,700,000

Proceeds from offering costs of private placement, gross

10,000,000

Offering costs

1,300,000

Liabilities marked to market value

$ 8,400,000

Additional income (loss) on liabilities

$ (2,400,000)

Reclassification of financing liabilities to stockholders equity

$ 8,400,000

March 2018 Private Placement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Offering costs

458,000

March 2018 Private Placement [Member] | Placement Agent [Member]

Class Of Warrant Or Right [Line Items]

Aggregate agent fee paid

850,000

March 2018 Private Placement [Member] | March 2018 Warrant Liability [Member]

Class Of Warrant Or Right [Line Items]

Liabilities marked to market value

4,600,000

2,400,000

Additional income (loss) on liabilities

(2,200,000)

$ 7,900,000

March 2018 Private Placement [Member] | March 2018 Securities Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued | shares

300,752

Warrant issued, shares of common stock called by warrant | shares

300,752

Warrants issued, exercise price | $ / shares

$ 45.75

Warrants expiration period

5 years

Applicable VWAP CalculationsI in Accordance with Registration [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued | shares

798,754

Warrant issued, shares of common stock called by warrant | shares

799,300

Warrants issued, exercise price | $ / shares

$ 17.2143

Applicable VWAP Calculations in Accordance Shareholder Approval [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued | shares

1,201,634

Warrant issued, shares of common stock called by warrant | shares

1,282,832

Warrants issued, exercise price | $ / shares

$ 10.7258

June 2018 Offering [Member] | June 2018 Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued | shares

1,392,345

Stock price | $ / shares

$ 9.93

Proceeds from issuance of common stock

$ 13,800,000

Offering closing period

Jun. 14, 2018

June 2018 Offering [Member] | Securities Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued | shares

1,489,575

Stock price | $ / shares

$ 4.91

Proceeds from issuance of common stock

$ 7,300,000

Offering closing period

Jun. 14, 2019

June 2018 Private Placement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

1,392,345

Warrants issued, exercise price | $ / shares

$ 9.94

Warrants expiration period

5 years 6 months

Proceeds from offering costs of private placement, gross

$ 174,000

Class of warrant or right number of securities called by warrants or rights, per share | $ / shares

$ 0.125

June 2019 Private Placement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

1,489,575

Warrants issued, exercise price | $ / shares

$ 5

Warrants expiration period

5 years 6 months

Proceeds from offering costs of private placement, gross

$ 186,000

Class of warrant or right number of securities called by warrants or rights, per share | $ / shares

$ 0.125

September 2019 Offering [Member]

Class Of Warrant Or Right [Line Items]

Issuance of placement agent warrants

$ 326,000

September 2019 Offering [Member] | Securities Purchase Agreement [Member]

Class Of Warrant Or Right [Line Items]

Shares of common stock issued | shares

1,318,828

Stock price | $ / shares

$ 7.52

Proceeds from issuance of common stock

$ 9,920,000

Offering closing period

Sep. 10, 2019

September 2019 Purchase Agreement [Member] | Warrants [Member]

Class Of Warrant Or Right [Line Items]

Warrant issued, shares of common stock called by warrant | shares

659,414

Warrants issued, exercise price | $ / shares

$ 7.52

Warrants expiration period

5 years 6 months

Proceeds from offering costs of private placement, gross

$ 82,000

Class of warrant or right number of securities called by warrants or rights, per share | $ / shares

$ 0.125

Stock-Based Compensation and _3

Stock-Based Compensation and Warrants - Additional Information (Detail)

Aug. 23, 2019

Aug. 22, 2019

May 20, 2015shares

May 14, 2015

Jun. 30, 2019shares

Apr. 30, 2019USD ($)$ / sharesshares

Dec. 31, 2013$ / sharesshares

Sep. 30, 2018

Dec. 31, 2019USD ($)IncentivePlan$ / sharesshares

Dec. 31, 2018USD ($)$ / sharesshares

Dec. 31, 2017shares

Jun. 30, 2014$ / sharesshares

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of equity incentive plans | IncentivePlan

2

Total number of options outstanding

661,701

530,044

288,129

Intrinsic value of options exercised | $

$ 0

$ 0

Total grant-date fair value of shares vested | $

2,200,000

1,300,000

Unrecognized compensation cost related to unvested stock-based compensation grants | $

$ 900,000

Weighted-average remaining recognition period

1 year 8 months 12 days

Stock-based compensation | $

$ 2,287,000

$ 1,550,000

Weighted-average estimated grant-date fair value of stock options granted | $ / shares

$ 5.13

$ 6.65

Number of warrant to purchase common stock issued

4,170,651

Warrants issued, exercise price | $ / shares

$ 9.18

Stock price | $ / shares

$ 32.52

Compensation expense associated with Warrants | $

$ 2,287,000

$ 1,550,000

Black Scholes Merton Model [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock price | $ / shares

$ 8.20

Service Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 6.18

Warrant issued, shares of common stock called by warrant

45,154

Warrants vesting period

12 months

Warrant, exercisable term

5 years

Fair value of Warrants | $

$ 224,000

Compensation expense associated with Warrants, term

1 year

Compensation expense associated with Warrants | $

$ 156,000

Performance Warrants [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 6.18

Warrant issued, shares of common stock called by warrant

100,000

Warrant, exercisable term

5 years

Fair value of Warrants | $

$ 497,000

Cumulative adjustment compensation expense associated with warrants | $

228,000

Compensation expense associated with Warrants | $

$ 352,000

Service and Performance Warrants [Member] | Black Scholes Merton Model [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants, measurement input

0.0237

Service and Performance Warrants [Member] | Black Scholes Merton Model [Member] | Expected Volatility [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants, measurement input

1.125

Service and Performance Warrants [Member] | Black Scholes Merton Model [Member] | Risk-Free Interest Rate [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock price | $ / shares

$ 6.18

Series D Redeemable Convertible Preferred Stock [Member] | Placement Agent [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 268.80

Warrant issued, shares of common stock called by warrant

1,674

Mahyco International [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 330.40

Warrant issued, shares of common stock called by warrant

3,784

Warrant, expiration date

Dec. 11, 2018

Investor [Member] | Series D Redeemable Convertible Preferred Stock [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 363.20

Warrant issued, shares of common stock called by warrant

61,397

2015 Employee Stock Purchase Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total number of shares reserved for issuance under plan

102,828

Stock-based compensation | $

$ 16,000

11,000

Percentage in payroll deductions to acquire shares of common stock

15.00%

Purchase plan offering period

6 months

Employees are able to purchase company's common stock on first trading day of offering period, percentage

85.00%

Issuance of common stock pursuant to employee stock purchase plan

15,389

First offering period, start date

May 14, 2015

First offering period, end date

Feb. 1, 2016

Selling, General and Administrative Expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Compensation expense associated with Warrants | $

$ 1,966,000

$ 1,171,000

Separation Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options exercisable period

2 years

90 days

Separation Agreement [Member] | Selling, General and Administrative Expenses [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Stock-based compensation | $

$ 438,000

March 2018 Purchase Agreement [Member] | Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

1,297,870

March 2018 Purchase Agreement [Member] | Purchase Agreement [Member] | Purchase Price of $10.7258 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

1,282,832

Warrants issued, purchase price of warrants per share | $ / shares

$ 10.7258

March 2018 Purchase Agreement [Member] | Purchase Agreement [Member] | Exercise Price of $41.5625 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

15,038

Warrants issued, exercise price | $ / shares

$ 41.5625

June 2018 Offering [Member] | Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

1,461,962

June 2018 Offering [Member] | Purchase Agreement [Member] | Purchase Price of $9.94 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

1,392,345

Warrants issued, purchase price of warrants per share | $ / shares

$ 9.94

June 2018 Offering [Member] | Purchase Agreement [Member] | Exercise Price of $12.568 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

69,617

Warrants issued, exercise price | $ / shares

$ 12.568

June 2019 Offering [Member] | Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

510,309

June 2019 Offering [Member] | Purchase Agreement [Member] | Purchase Price of $5.00 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

435,830

Warrants issued, purchase price of warrants per share | $ / shares

$ 5

June 2019 Offering [Member] | Purchase Agreement [Member] | Exercise Price of $6.2938 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

74,479

Warrants issued, exercise price | $ / shares

$ 6.2938

September 2019 Offering [Member] | Purchase Agreement [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

725,356

September 2019 Offering [Member] | Purchase Agreement [Member] | Purchase Price of $7.52 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

659,414

Warrants issued, purchase price of warrants per share | $ / shares

$ 7.52

September 2019 Offering [Member] | Purchase Agreement [Member] | Exercise Price of $9.4781 [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Number of warrant to purchase common stock issued

65,942

Warrants issued, exercise price | $ / shares

$ 9.4781

2015 Omnibus Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Terms under the plan

The 2015 Plan became effective upon the Company’s IPO in May 2015 and all shares that were reserved, but not issued, under the 2006 Plan were assumed by the 2015 Plan. Upon effectiveness, the 2015 Plan had 154,387 shares of common stock reserved for future issuance, which included 10,637 that were transferred to and assumed by the 2015 Plan. The 2015 Plan provides for automatic annual increases in shares available for grant. In addition, shares subject to awards under the 2006 Plan that are forfeited or canceled will be added to the 2015 Plan.

Total number of shares reserved for issuance under plan

154,387

675,340

Options vesting period

4 years

2 years

Additional shares authorized for issuance under the plan

120,000

Common stock available for future grant

58,868

Total number of options outstanding

616,472

2006 Stock Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Total number of shares reserved for issuance under plan

10,637

Total number of options outstanding

45,229

Maximum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrant, expiration date

2025-03

Maximum [Member] | 2015 Omnibus Equity Incentive Plan [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Options exercisable period

10 years

Minimum [Member]

Share-based Compensation Arrangement by Share-based Payment Award [Line Items]

Warrants issued, exercise price | $ / shares

$ 8.322

Warrant, expiration date

2020-07

Stock-Based Compensation and _4

Stock-Based Compensation and Warrants - Summary of Activity Under Stock Incentive Plans (Detail) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Shares Subject to Outstanding, Beginning Balance	530,044	288,129
Shares Subject to Outstanding, Options granted	208,571	302,077
Shares Subject to Outstanding, Options exercised	(546)	(44,354)
Shares Subject to Outstanding, Options Forfeited	(30,132)	(4,006)
Shares Subject to Outstanding, Options Expired	(46,236)	(11,802)
Shares Subject to Outstanding, Ending Balance	661,701	530,044
Shares Subject to Outstanding, Vested and expected to vest	654,170
Shares Subject to Outstanding, Exercisable	410,270
Weighted-Average Exercise Price Per Share, Outstanding Beginning Balance	$ 35.53	$ 63.62
Weighted-Average Exercise Price Per Share, Options granted	5.13	6.65
Weighted-Average Exercise Price Per Share, Options exercised	4.63	21.73
Weighted-Average Exercise Price Per Share, Options forfeited	33.95	14.21
Weighted-Average Exercise Price Per Share, Options expired	98.69	43.73
Weighted Average Exercise Price Per Share, Outstanding Ending Balance	21.60	$ 35.53
Weighted Average Exercise Price Per Share, Vested and expected to vest	21.74
Weighted Average Exercise Price Per Share, Exercisable	$ 29.24
Aggregate Intrinsic Value, Outstanding Balance	$ 305
Aggregate Intrinsic Value, Vested and expected to vest	301
Aggregate Intrinsic Value, Exercisable	$ 192

Stock-Based Compensation and _5

Stock-Based Compensation and Warrants - Weighted-Average Fair Value Assumption of Stock Option Awards (Detail) - Employee Stock Option [Member]	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term (years)	7 years 14 days	5 years 11 months 26 days
Expected volatility	99.00%	99.00%
Risk-free interest rate	2.01%	2.95%

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail)	Dec. 31, 2010USD ($)Program	Dec. 31, 2019USD ($)	Dec. 31, 2019USD ($)	Dec. 31, 2018USD ($)	Jun. 15, 2005USD ($)
Commitments And Contingencies [Line Items]
Other noncurrent liability		$ 2,000,000	$ 2,000,000	$ 3,072,000
Royalties due to both related and unrelated parties on license revenue accrued		266,000	266,000	216,000
Milestones payments yet to be achieved			2,000,000	2,000,000
Milestones payment			$ 0	$ 0
Anawah, Inc [Member]
Commitments And Contingencies [Line Items]
Contingent liability	$ 3,000,000				$ 5,000,000
Date of merger and reorganization			Jun. 15, 2005
Restructuring activities, description			As of December 31, 2010, the Company ceased activities relating to three of the six Anawah product programs
Number of development programs ceased | Program	3
Number of development programs | Program	6
Other noncurrent liability		2,000,000	$ 2,000,000
Gain on abandon of technologies		$ 1,000,000
Minimum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		1 year	1 year
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements			2.00%
Maximum [Member]
Commitments And Contingencies [Line Items]
Operating leases, term of contract		5 years	5 years
Royalty payments due, percentage of net revenue as defined in the In-Licensing agreements			15.00%

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Minimum Funding Requirements Under Non-Cancelable Agreement (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Operating Leases Future Minimum Payments Due [Abstract]
2020	$ 500
2021	750
Total	$ 1,250

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019
Lessee Lease Description [Line Items]
Operating lease liability	$ 2,108
ROU asset	$ 1,963
Existence of option to extend	true
Lease option to extend, description	Some leases (the Davis office, warehouse, greenhouse and a copy machine) include one or more options to renew, with renewal terms that can extend the lease term from one to six years.
Rent expense under Topic 840		$ 1,300
Minimum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	1 year
Maximum [Member]
Lessee Lease Description [Line Items]
Option to extend lease, term	6 years
ASU No. 2016-02 [Member]
Lessee Lease Description [Line Items]
Operating lease liability	$ 200		$ 2,400
ROU asset	$ 200		$ 2,300

Leases - Schedule of Leases (De

Leases - Schedule of Leases (Detail) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Assets
Operating lease assets	$ 1,963
Total leased assets	1,963
Liabilities
Current - Operating	611
Noncurrent - Operating	1,497
Total leased liabilities	2,108
Lease Cost
Net lease cost	$ 858
Lease Term and Discount Rate
Weighted-average remaining lease term (years)	2 years 7 months 6 days
Weighted-average discount rate	7.00%
SG&A and R&D Expenses [Member]
Lease Cost
Operating lease cost	$ 708
Sublease income	(55)
R&D Expenses [Member]
Lease Cost
Short term lease cost	$ 205

Leases - Schedule of Maturities

Leases - Schedule of Maturities of Operating Lease Liabilities (Detail) $ in Thousands	Dec. 31, 2019USD ($)
Lessee Disclosure [Abstract]
2020	$ 735
2021	681
2022	575
2023	372
Total operating lease payments	2,363
Less: imputed interest	255
Total current and noncurrent operating lease liabilities	$ 2,108

Income Taxes - Components of Lo

Income Taxes - Components of Loss Before Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Domestic	$ (28,871)	$ (13,470)
Foreign	0	0
Loss before income taxes	$ (28,871)	$ (13,470)

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Schedule Of Income Tax [Line Items]
Total income tax expense	$ 2,000	$ 10,000
Decrease in net valuation allowance	$ (25,900,000)	$ 3,200,000
Operating loss carryforwards limitations on use	it has not forfeited the right to carryforward tax losses up to 20 years
Tax years subject to examination to extent of NOLs being carried forward	2000
Uncertain Tax Position	$ 0
Maximum [Member]
Schedule Of Income Tax [Line Items]
Right to carryforward tax losses, period	20 years
Tax year subject to examination by the tax authorities	2019
Minimum [Member]
Schedule Of Income Tax [Line Items]
Tax year subject to examination by the tax authorities	2000
Federal [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 186,600,000
Operating loss carryforward generated	186,600,000
Operating loss carryforward unutilized	7,200,000
Operating loss carryforward expected to be unavailable	130,500,000
State [Member]
Schedule Of Income Tax [Line Items]
Aggregate amount of net operating loss	$ 47,900,000

Income Taxes - Schedule of Inco

Income Taxes - Schedule of Income Tax Expense Comprised of Current State Taxes and Foreign Taxes (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Current:
Federal	$ 0	$ 0
State	2,000	1,000
Foreign	0	9,000
Total current tax expense	2,000	10,000
Deferred:
Federal	0	0
State	0	0
Foreign	0	0
Total deferred tax asset	0	0
Total tax expense	$ 2,000	$ 10,000

Income Taxes - Reconciliation o

Income Taxes - Reconciliation of Statutory Federal Income Tax Rate to the Company's Effective Tax Rate (Detail)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Expected income tax provision at the federal statutory rate	21.00%	21.00%
State taxes, net of federal benefit	5.30%	8.50%
Change in valuation allowance	(26.40%)	(27.30%)
Transaction costs	0.00%	(2.90%)
Related offering costs	(0.50%)	(1.10%)
Excess windfall benefit	0.00%	1.40%
Withholding taxes	0.00%	(0.10%)
Other	0.60%	0.40%
Income tax provision	0.00%	(0.10%)

Income Taxes - Summary of Compa

Income Taxes - Summary of Company's Deferred Tax Assets (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Deferred tax assets:
Net operating loss carryforwards	$ 13,267	$ 42,097
Unearned revenue	11	26
Stock-based compensation	3,384	2,855
Accrued payroll and benefits	224	255
Research and development credits	0	171
Fixed asset basis difference	90	114
Inventory reserve	568	508
Operating lease liability	565	0
Common stock warrant assets	988	0
Charitable contributions	2	3
Total deferred tax assets	19,099	46,029
Deferred tax liabilities:
Right of use asset	(526)	0
Common stock warrant liabilities	0	(1,529)
Total deferred tax liabilities	(526)	(1,529)
Less valuation allowance	(18,573)	(44,500)
Net deferred tax assets	$ 0	$ 0

Retirement Benefits - Additiona

Retirement Benefits - Additional Information (Detail) - USD ($)	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Compensation And Retirement Disclosure [Abstract]
Employer matching contribution, percent	50.00%
Maximum annual contribution per employee, percent	3.00%
Description of defined contribution pension and other postretirement plans	Employees’ rights to employer contributions vest on the one-year anniversary of their date of employment.
Defined benefit plan employee vested minimum period, years	1 year
Amount accrued for company's approved discretionary match	$ 0	$ 0

Segment and Geographic Informat

Segment and Geographic Information - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2019Segment
Segment Reporting [Abstract]
Number of operating segment	1

Segment and Geographic Inform_2

Segment and Geographic Information - Summary of Revenues Based on Location of Customers (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 1,169	$ 1,464
United States
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	722	1,168
India
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	7	90
Africa
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	182	115
Canada
Revenues From External Customers And Long Lived Assets [Line Items]
Total revenues	$ 258	$ 91

Net Loss per Share - Summary of

Net Loss per Share - Summary of Securities Not Included in Diluted Per Share Calculations (Detail) - shares	12 Months Ended
	Dec. 31, 2019	Dec. 31, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	4,832,352	3,352,947
Option to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	661,701	530,044
Warrants to purchase common stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities not included in the diluted per share calculations, amount	4,170,651	2,822,903

Related Party Transactions - Ad

Related Party Transactions - Additional Information (Detail) - USD ($) $ in Thousands	Dec. 31, 2019	Dec. 31, 2018
Related Party Transaction [Line Items]
Royalty fees due	$ 40	$ 29
John Sperling Foundation [Member]
Related Party Transaction [Line Items]
Royalty fees due	$ 40	$ 29

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event	1 Months Ended
	Jan. 31, 2020
Subsequent Event [Line Items]
Description of operating lease expected to be commence	second quarter of 2020
Lessee operating lease option to extend to be commence	extended the term through April 2025
Lessee, Operating Lease, Lease Not yet Commenced, Existence of Option to Extend [true false]	true
Lessee operating lease renewal term to be commence	5 years